Document:

EX-10.2

 Exhibit 10.2 

CONFIDENTIAL TREATMENT REQUESTED 

CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN REDACTED AND HAVE BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. INFORMATION THAT WAS
OMITTED IN THE EDGAR VERSION HAS BEEN NOTED IN THIS DOCUMENT WITH A PLACEHOLDER IDENTIFIED BY THE MARK “[***]”. 
  

							
	
    AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT
	  	  

1. CONTRACT ID CODE            
	 	  

    PAGE OF PAGES            

	  	 	 	    1    	 	    18    

 

															
	  

    2. AMENDMENT/MODIFICATION NO.    

    0006
	 	 	 	    3. EFFECTIVE DATE                 
   
     See Block 16C
	 	
    4. REQUISITION/PURCHASE REQ. NO.        

    OS219059
	 	5. PROJECT NO, (If applicable)	  

	
    6.ISSUED BY              
          
	 	CODE        	 	  HHS/OS/ASPR/BARDA                   	 	7. ADMINISTERED BY (If other than Item 6)          CODE    	 		 	 	    ASPR-BARDA02	 
	  

    US DEPT OF HEALTH & HUMAN SERVICES

    ASST SEC OF PREPAREDNESS & RESPONSE

    ACQ MANAGEMENT, CONTRACTS, & GRANTS

    O’NEILL HOUSE OFFICE BUILDING

    Washington DC 20515

 
	 	  

US DEPT OF HEALTH & HUMAN SERVICES

ASST SEC OF PREPAREDNESS & RESPONSE

ACQ MANAGEMENT, CONTRACTS, & GRANTS

O’NEILL HOUSE OFFICE BUILDING

Washington DC 20515
  
	 	 	 	 
	    8. NAME AND ADDRESS OF CONTRACTOR (No., street, county, State and ZIP code)	 	(x) 	 	     9A. AMENDMENT OF SOLICITATION NO.

 
	  

	 PFENEX, INC 1358378

PFE6NEX INC. 10790 ROSELLE ST
 10790 ROSELLE
ST
 SAN DIEGO CA 921211508
	 	 	 	     9B. DATED (SEE ITEM 11)

 
	  

	 	X	 	     10A. MODIFICATION OF CONTRACT/ORDER NO.

 
     HHSO100201500011C

 
	  

  

	 	 	 	     10B. DATED (SEE ITEM 13)

    08/14/2015
  
	 		 			
	    CODE 1358378	 	   FACILITY CODE     	 	 	 	 	 	 	 	 
	 11. THIS ITEM ONLY
APPLIES TO AMENDMENTS OF SOLICITATIONS
	 	 	 	 	 	 

											
	  
 ☐ The above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of
Offers                 ☐    is
extended,                ☐    is not extended.

 
 Offers must acknowledge receipt of this amendment prior to the hour and date
specified in the solicitation or as amended, by one of the following methods: (a) By completing Items 8 and 15, and returning              copies of the amendment; (b)
By acknowledging receipt of this amendment on each copy of the offer submitted; or (c) By separate letter or telegram which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGEMENT TO BE RECEIVED AT THE PLACE
DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted, such change may be made by telegram or letter, provided
each telegram or letter makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified

	     12 ACCOUNTING AND APPROPRIATION DATA (if required)

 
     See Schedule
	 	Net Increase:	  	$1,737,505.23
	    13. THIS ITEM ONLY APPLIES TO MODIFICATION OF CONTRACTS/ORDERS. IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM
14.

			
	
    CHECK ONE   
	  	 A. THIS CHANGE ORDER IS ISSUED PURSUANT TO:
(Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A.

	 
	 	  	 B. THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT
THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(b).
  

	     X   
	  	 C.   THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO
PURSUANT TO AUTHORITY OF:
 52.243-5 Alternate 1 Changes-Cost-reimbursement and Mutual agreement of the parties

	 	  	 D.   OTHER (Specify type of modification and
authority)
  

	     E.
IMPORTANT:      Contractor        ☐    is not        ☒    is required to sign this document and return     1     copies to the issuing office.

 

	 14. DESCRIPTION OF AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract
subject matter where feasible.)

     Tax ID Number: 27-1356759 

    DUNS Number: 013603710 

    1. The purpose of this modification is to add additional funding in the amount of $1,737,505.23 for CLIN 0005. 

    Continued . . . 
     Except as
provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains unchanged and in full force and effect. 
  

							
	
    15A. NAME AND TITLE OF SIGNER (Type or print)

 
     SUSAN A. KNUDSON CFO
	  	 16A. NAME AND TITLE OF CONTRACTING OFFICER (Type or
print)
  
 WENDELL CONYERS

	     15B. CONTRACTOR/OFFEROR

 

    /s/ Susan. A Knudson                 
                           

                            
(Signature of person authorized to sign)
	  	 15C. DATE SIGNED
  

05/10/2018
	  	 16B. UNITED STATES OF AMERICA

 

/s/ Wendell Conyers                      
          
               (Signature of
Contracting Officer)
	  	 16C. DATE SIGNED

 
 05/15/2018

  

					
	 NSN 7540-01-152-8070

PREVIOUS EDITION UNUSABLE
	  		  	 STANDARD FORM 30 (REV. 10-83)
 Prescribed by GSA

FAR (48 CFR) 53.243

 [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions. 

													
	CONTINUATION SHEET	 	REFERENCE NO. OF DOCUMENT BEING CONTINUED	  	PAGE	  	OF
	 	HHSO100201500011C/0006	  	 	  	 	  	 	  	2	  	18
	 NAME OF OFFEROR OR CONTRACTOR

PFENEX, INC 1358378

											
	 	 	 	 	 	 
	
ITEM NO.

(A)
	  	SUPPLIES/SERVICES
(B)	  	 QUANTITY

(C)
	  	 UNIT

(D)
	  	 UNIT PRICE

(E)
	  	 AMOUNT

(F)

	 	  	Period of Performance: 08/14/2015 to 8/09/2020	  	 	  	 	  	 	  	
	 	 	 	 	 	
	 	  	Change Item 5 to read as follows (amount shown is the obligated amount):	  	 	  	 	  	 	  	
	 	 	 	 	 	
	5	  	Option 4 — MANUFACTURING PROCESS OPTIMIZATION
Obligated Amount: $1,737,505.23	  	 	  	 	  	 	  	1,737,505.23
	 	 	 	 	 	
	 	  	 Accounting info

 
 2017.1992017.25103 Appr. Yr.: 2017 CAN: 1992017 Object Class: 25103

Funded: $2,437,723.00
 Accounting Info: Object Class: 25106

2018.1992018.25106 Appr. Yr.: 2018 CAN: 1992018
 Funded:
$1,737,505.23
	  	 	  	 	  	 	  	 

					
	 Contract No. HHSO100201600009C

Modification #06
	  	Continuation Sheet Block 14	  	Page 3 of 18

 SUMMARY OF CHANGES 
 Beginning
with the effective date of this modification, the Government and Contractor mutually agree as follows: 
  

	1.	 Add an additional funding to CLIN 005 in order to provide necessary funding to Pfenex to [***].

 *When submitting an invoice for this work please reference this requisition number: OS219059. These funds must be
tracked separate from other funds on CLIN 0005. 
  

	2.	 Delete and replace ARTICLE B.3. OPTION PRICES due to the request for additional funds for CLIN 0005, Option 4
period of performance: 

  

																							
	 CLIN
	 	Option	  	Estimated
Period of Parf.	 	  	Supplies/
Services	  	Total Est
Cost	 	  	Fixed Fee	 	  	Total
Est. Cost
Plus
Fixed Fee	 	  	Exercised
Yes/No
	0002	 	1	  	 
	08/12/2015-
11/03/2016	
 	  	[***]	  	$	2,480,823	 	  	$	148,849	 	  	$	2,629,672	 	  	No
	0003	 	2	  	 
 
	11/24/2016-
 02/24/2019
	 
  
	  	[***]	  	$	12,966,402	 	  	$	777,984	 	  	$	13,744,386	 	  	No
	0004	 	3	  	 
 
	05/27/2018-
 08/02/2020
	 
  
	  	[***]	  	$	44,230,173	 	  	$	2,653,810	 	  	$	46,883,983	 	  	No
	0005	 	4	  	 
 
	12/22/2016-
 12/31/2019
	 
  
	  	[***]	  	$	4,037,244	 	  	$	137,984	 	  	$	4,175,228	 	  	Yes
	0006	 	5	  	 
 
	12/22/2016-
 09/30/2018
	 
  
	  	[***]	  	$	2,304,571	 	  	$	138,274	 	  	$	2,442,845	 	  	Yes
	0007	 	6	  	 
 
	01/09/2016-
 08/05/2020
	 
  
	  	[***]	  	$	14,107,610	 	  	$	846,457	 	  	$	14,954,067	 	  	No
	0008	 	7	  	 
 
	11/24/2016-
 08/09/2020
	 
  
	  	[***]	  	$	41,202,354	 	  	$	2,472,141	 	  	$	43,674,496	 	  	No
	0009	 	8	  	 
 
	12/24/2016-
 05/13/2017
	 
  
	  	[***]	  	$	750,622	 	  	$	45,037	 	  	$	795,659	 	  	No

  

	3.	 Delete and replace ARTICLE B.4. LIMITATIONS APPLICABLE to DIRECT COSTS 

(b)    Travel Costs 

Total expenditures for travel (transportation, lodging, subsistence, and incidental expenses) incurred in direct performance of this contract
during the base segment and all options exercised (CLINs 0001, 0005 and 0006) shall not exceed $58,093.00 without the prior written approval of the Contracting Officer. The Contractor shall notify the Contracting Officer in writing when travel
expenditures have exceeded 80% of each segment (CLIN) travel expenses. Cost must be consistent with Federal Acquisition Regulations (FAR) 52.247-63 — Preference for U.S. Air Flag carriers (See
chart below) 
  

	4.	 Funding Total Summary: the total funded amount on the contract changed from $20,772,168.00 to $22,509,673.23.

  

	5.	 Contract Total Summary (if all options are exercise): the total contract value changed from
$143,454,431 to $145,191,936. 

  

	6.	 Section J (Attachment 1) SOW: Delete and replace the entire SOW: Updated 20 March 2018

 Topic Area of Interest No. 1. 

Contractual Statement of Work 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 PREAMBLE 

Independently and not as an agency of the Government, the Contractor shall be required to furnish all the necessary services, qualified personnel, material,
equipment, and facilities, not otherwise provided by the Government, as needed to perform the Statement of Work submitted in response to the BARDA Broad Agency Announcement (BAA) BAA-13-100-SOL-00013. 
 The Government reserves the right to modify
the milestones, progress, schedule, budget, or deliverables to add or delete deliverables, process, or schedules if the need arises. Because of the nature of this research and development (R&D) contract and the complexities inherent in this and
prior programs, at designated milestones the Government will evaluate whether work should be redirected, removed, or whether schedule or budget adjustments should be made. The Government reserves the right to change the product, process, schedule,
or events to add or delete part or all of these elements as the need arises. 
 Overall Objectives and Scope 

[***]: 
 Base Period - [***] 

Option Period 1— [***] 
 Option Period 2 — [***] 

Option Period 3 — [***] 
 Option Period 4 — [***] 

Option Period 5 — [***] 
 Option Period 6 — [***] 

Option Period 7 — [***] 
 Option Period 8 — [***] 

WBS 1 BASE PERIOD - [***] 
 [***] 

WBS 1.1 Program Management 
 DURATION:
[***] 
 The Contractor shall provide for the following, as outlined below and in the contract deliverables list (Article F.2), for the base period and all
options: 
 [***] 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.EX-10.3

 Exhibit 10.3 

Execution Version 

CONFIDENTIAL TREATMENT REQUESTED 

CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN REDACTED AND HAVE BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. INFORMATION THAT WAS
OMITTED IN THE EDGAR VERSION HAS BEEN NOTED IN THIS DOCUMENT WITH A PLACEHOLDER IDENTIFIED BY THE MARK “[***]”. 
 DEVELOPMENT
AND LICENSE AGREEMENT 
 by and between 

PFENEX INC. 
 and

 ALVOGEN MALTA OPERATIONS LTD. 

June 11, 2018 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 Table of Contents 

 

							
	 	 	 	  	Page	 
	 ARTICLE I DEFINITIONS / INTERPRETATION
	  	 	1	 
			
	 Section 1.1
	 	Defined Terms	  	 	1	 
	 Section 1.2
	 	Additional Definitions	  	 	10	 
	 Section 1.3
	 	Interpretation	  	 	12	 
		
	ARTICLE II GRANT OF LICENSE	  	12	 
			
	 Section 2.1
	 	Product License	  	 	12	 
	 Section 2.2
	 	Sublicenses	  	 	13	 
	 Section 2.3
	 	No Implied Licenses; Retained Rights	  	 	13	 
	 Section 2.4
	 	Non-Competition	  	 	14	 
		
	 ARTICLE III DEVELOPMENT / REGULATORY ACTIVITIES
	  	 	14	 
			
	 Section 3.1
	 	Pfenex Responsibilities	  	 	14	 
	 Section 3.2
	 	Alvogen Responsibilities	  	 	14	 
	 Section 3.3
	 	Coordination; Assistance; Subcontracting	  	 	15	 
	 Section 3.4
	 	Regulatory Materials	  	 	16	 
		
	 ARTICLE IV PAYMENTS
	  	 	18	 
			
	 Section 4.1
	 	Upfront License Payment	  	 	18	 
	 Section 4.2
	 	Support Payments	  	 	18	 
	 Section 4.3
	 	Approval Payment	  	 	19	 
	 Section 4.4
	 	Therapeutically Equivalent Milestone Payment	  	 	19	 
	 Section 4.5
	 	Profit Share	  	 	19	 
	 Section 4.6
	 	Reports	  	 	20	 
	 Section 4.7
	 	Payment Terms	  	 	20	 
	 Section 4.8
	 	Records; Audit Rights	  	 	20	 
	 Section 4.9
	 	Costs	  	 	21	 
	 Section 4.10
	 	Annual Reconciliation and True-up	  	 	21	 
		
	 ARTICLE V MANUFACTURE OF PRODUCT; SALES AND MARKETING
	  	 	21	 
			
	 Section 5.1
	 	Manufacturing Responsibility	  	 	21	 
	 Section 5.2
	 	Manufacturing Cooperation	  	 	22	 
	 Section 5.3
	 	Product Packaging and Labeling	  	 	22	 
	 Section 5.4
	 	Product Documentation	  	 	22	 
	 Section 5.5
	 	Product Recalls	  	 	22	 
	 Section 5.6
	 	Product Pricing and Promotion; Agency Contacts	  	 	22	 
	 Section 5.7
	 	Sales and Marketing	  	 	23	 
	 Section 5.8
	 	Ex-Territory Sales; Export Monitoring	  	 	23	 
		
	 ARTICLE VI PRODUCT TRADEMARK; INTELLECTUAL PROPERTY LITIGATION
	  	 	23	 
			
	 Section 6.1
	 	Product Trademarks	  	 	23	 
	 Section 6.2
	 	Ownership of Product Inventions	  	 	24	 
	 Section 6.3
	 	Patent Prosecution and Maintenance of Product Inventions	  	 	25	 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

i 

 Table of Contents 

(continued) 
  

							
	 	 	 	  	Page	 
	 Section 6.4
	 	 Third Party Actions
	  	 	25	 
	 Section 6.5
	 	 Enforcement Actions
	  	 	26	 
	 Section 6.6
	 	 Patent Extensions; Orange Book Listings; Patent Certifications
	  	 	27	 
	 Section 6.7
	 	 Reimbursement Requirements
	  	 	28	 
	 Section 6.8
	 	 Recovered Amounts
	  	 	28	 
	 Section 6.9
	 	 Common Interest Agreement
	  	 	28	 
	 Section 6.10
	 	 Patent Marking
	  	 	28	 
		
	 ARTICLE VII EXECUTIVE STEERING COMMITTEE
	  	 	28	 
			
	 Section 7.1
	 	 Formation and Purpose
	  	 	28	 
	 Section 7.2
	 	 Membership
	  	 	28	 
	 Section 7.3
	 	 Meeting Requirements
	  	 	29	 
	 Section 7.4
	 	 Decision-Making; Dispute Resolution
	  	 	29	 
	 Section 7.5
	 	 Meeting Minutes
	  	 	30	 
	 Section 7.6
	 	 Expenses
	  	 	31	 
	 Section 7.7
	 	 Working Committees
	  	 	31	 
	 Section 7.8
	 	 Committee Authority
	  	 	31	 
	 Section 7.9
	 	 Day-to-Day
Responsibilities
	  	 	31	 
	 Section 7.10
	 	 Cooperation; Withdrawal
	  	 	31	 
		
	 ARTICLE VIII CONFIDENTIALITY; TAXES; NONSOLICITATION; PUBLICATIONS
	  	 	32	 
			
	 Section 8.1
	 	 Confidentiality
	  	 	32	 
	 Section 8.2
	 	 Agents
	  	 	33	 
	 Section 8.3
	 	 Restrictions on Sharing Information
	  	 	33	 
	 Section 8.4
	 	 Prior Agreements
	  	 	33	 
	 Section 8.5
	 	 Taxes
	  	 	34	 
	 Section 8.6
	 	 Nonsolicitation
	  	 	35	 
	 Section 8.7
	 	 Public Announcements
	  	 	35	 
	 Section 8.8
	 	 Publications
	  	 	36	 
		
	 ARTICLE IX REPRESENTATIONS, WARRANTIES AND COVENANTS
	  	 	36	 
			
	 Section 9.1
	 	 Representations and Warranties of Pfenex
	  	 	36	 
	 Section 9.2
	 	 Representations and Warranties of Alvogen
	  	 	40	 
	 Section 9.3
	 	 Covenants
	  	 	41	 
	 Section 9.4
	 	 Disclaimer of Warranties
	  	 	42	 
	 Section 9.5
	 	 Insurance
	  	 	42	 
		
	 ARTICLE X TERM; TERMINATION
	  	 	43	 
			
	 Section 10.1
	 	 Term
	  	 	43	 
	 Section 10.2
	 	 Termination
	  	 	43	 
	 Section 10.3
	 	 General Effects of Expiration or Termination
	  	 	44	 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

ii 

 Table of Contents 

(continued) 
  

							
	 	 	 	  	Page	 
	 Section 10.4
	 	 Additional Effects of Expiration or Termination
	  	 	44	 
	 Section 10.5
	 	 Additional Effects of Specific Terminations
	  	 	45	 
		
	 ARTICLE XI INDEMNIFICATION AND LIABILITY LIMITS
	  	 	46	 
			
	 Section 11.1
	 	 Indemnification by Pfenex
	  	 	46	 
	 Section 11.2
	 	 Indemnification by Alvogen
	  	 	46	 
	 Section 11.3
	 	 Indemnification Procedure
	  	 	47	 
	 Section 11.4
	 	 Limitations on Liability
	  	 	48	 
	 Section 11.5
	 	 Product Liability Allocation
	  	 	50	 
	 Section 11.6
	 	 Cooperation
	  	 	50	 
		
	 ARTICLE XII MISCELLANEOUS
	  	 	50	 
			
	 Section 12.1
	 	 Force Majeure
	  	 	50	 
	 Section 12.2
	 	 Notices
	  	 	51	 
	 Section 12.3
	 	 Governing Law
	  	 	52	 
	 Section 12.4
	 	 Internal Dispute Resolution
	  	 	52	 
	 Section 12.5
	 	 Arbitration
	  	 	52	 
	 Section 12.6
	 	 Relationship of the Parties
	  	 	52	 
	 Section 12.7
	 	 Assignment
	  	 	53	 
	 Section 12.8
	 	 Binding Effect
	  	 	53	 
	 Section 12.9
	 	 Entire Agreement; Amendments
	  	 	53	 
	 Section 12.10
	 	 Severability
	  	 	53	 
	 Section 12.11
	 	 Waiver
	  	 	53	 
	 Section 12.12
	 	 English Language
	  	 	54	 
	 Section 12.13
	 	 Counterparts
	  	 	54	 
	 Section 12.14
	 	 Electronic Execution and Delivery
	  	 	54	 
	 Section 12.15
	 	 Bankruptcy License Protection
	  	 	54	 
	 Section 12.16
	 	 Further Assurances
	  	 	55	 
	 Section 12.17
	 	 Compliance with Applicable Laws
	  	 	55	 
	 Section 12.18
	 	 Expenses
	  	 	55	 
	 Section 12.19
	 	 Third Party Beneficiaries
	  	 	55	 
	 Section 12.20
	 	 Equitable Remedies
	  	 	55	 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

iii 

 DEVELOPMENT AND LICENSE AGREEMENT 

This Development and License Agreement (this “Agreement”) is entered into as of June 11, 2018 (the “Effective
Date”) by and between Pfenex Inc., a Delaware corporation (“Pfenex” or a “Party”), and Alvogen Malta Operations Ltd., a Maltese corporation (“Alvogen” or a “Party”, and
together with Pfenex, the “Parties”). 
 BACKGROUND 

A.    Pfenex is a clinical stage biotechnology company engaged in the development of difficult to manufacture and
high-value proteins, focusing on biosimilar therapeutics, including Product (as defined below); 
 B.    Alvogen
has expertise in the development, manufacture, and Commercialization of pharmaceutical products for human use in the Territory (as defined below); and 

WHEREAS, Alvogen wishes to obtain from Pfenex, and Pfenex wishes to grant to Alvogen, an exclusive right to develop, manufacture, and
Commercialize Product in the Territory, subject to the terms and conditions set forth herein. 
 NOW, THEREFORE, in consideration of
the mutual promises, covenants and agreements set forth herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Pfenex and Alvogen agree as follows: 

ARTICLE I 
 DEFINITIONS /
INTERPRETATION 
 Section 1.1    Defined Terms. The following words and phrases, when used herein with
initial capital letters, have the meanings set forth or referenced below: 
 “Accounting Standards” means, with respect to
a Person, then current generally accepted accounting principles consistently applied by such Person across its operations, including United States GAAP and International Financial Reporting Standards. 

“Acquiring Entity” means a Third Party (including the parent company of such Third Party, as applicable) that merges or
consolidates with or acquires Pfenex, or to which Pfenex transfers all or substantially all its assets to which this Agreement pertains (any such merger, consolidation or acquisition, the “Acquisition Transaction”). 

“Action” means any proceeding, action, claim (formal or informal, including by way of a letter), arbitration, administrative
or regulatory action or other type of legal action, whether taken as a plaintiff or an initiating party (including through a request for declaratory judgment) or by way of counter-claim or defense. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

1 

 “Adverse Drug Responses” shall be defined in more detail in any PV
Agreement to include any “Adverse Drug Experience” as defined in the then-current 21 C.F.R. Section 314.80 and “Adverse Drug Responses” as defined in the then-current guidelines and regulations promulgated by the ICH
(International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use). 

“Affiliate” means any Person controlled by, controlling or under common control with another Person; provided, however, that
(i) any direct or indirect stockholder of a Party that is a financial sponsor, professional investor, or investment fund (of whatever nature) and (ii) any portfolio companies or investments that is held, controlled or managed by any Person
described in clause (i) shall, in each of cases (i) and (ii), be deemed to not be an Affiliate of such Party for purposes of this Agreement. For purposes of this definition, “control” means (a) direct or indirect beneficial
ownership of fifty percent (50%) or more of the voting stock in Person, or (b) the possession, directly or indirectly, of any other power to direct or cause the direction of the management and policies of such Person, whether through ownership
of voting securities, by contract or otherwise. 
 “Alvogen’s Knowledge” means the actual knowledge, after
reasonable inquiry, of the President, Chief Financial Officer, Vice President of Legal Affairs, and Vice President of Business Development, in each case of Alvogen Inc., a Delaware corporation. 

“ANDA” means an Abbreviated New Drug Application pursuant to 21 U.S.C. § 355(j) et seq., and the regulations
promulgated thereunder, as such application may be amended or supplemented from time to time. 
 “Annual Period” means
(a) for calendar year 2018, the period commencing on the Effective Date and ending on December 31, 2018 (or the date this Agreement is terminated if such termination occurs prior to December 31, 2018), (b) for each successive
calendar year during the Term (other than the calendar year in which the Term expires or this Agreement is terminated) the period beginning on January 1st of such year and ending on December 31st of such year, and (c) for the calendar
year (other than 2018) in which the Term expires or this Agreement is terminated, the period beginning on January 1st of such calendar year and ending on the effective date of the termination of this Agreement. 

“Applicable Law” means each applicable federal, state, local or foreign constitution, treaty, law, statute, ordinance, rule,
regulation, directive, policy, order, writ, award, decree, injunction, judgment, stay or restraining order of any Governmental Authority (including the FDA), the terms of any NDA Approval, and any other ruling or decision of, agreement with or by,
or requirement of any Governmental Authority. 
 “Assignee” means any Person (other than Pfenex and Alvogen) that is
assigned or transferred, or succeeds to, any rights under this Agreement. 
 “Average Sale Price” means, with respect to a
particular country and particular period, the weighted average sale price of Product, Bundled Product or other product or service included in a Bundled Product, as applicable, as determined by dividing (a) the Net Sales on commercial sales of
such Product or Bundled Product or net sales of other product or service 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

2 

 
included in a Bundled Product in arms-length transactions in the applicable country during the applicable period, by (b) the units of such Product, Bundled Product or other products or
services included in a Bundled Product commercially sold in arms-length transactions in such country during such period. 
 “Bundled
Product” means Product sold together with any other product(s) or service(s) at a single unit price, whether packaged together or separately, and which other product(s) or service(s) have material independent value from Product itself. 

“Business” means the research, development, manufacture and Commercialization of and specific to, Product in the Territory by
or on behalf of Pfenex, Alvogen and their respective Affiliates and subcontractors, either individually or jointly. 
 “Business
Day” means any day other than a Saturday, Sunday or a holiday on which banks in the United States are authorized by Applicable Law to be closed. 

“cGxP” means then-current good manufacturing, clinical or laboratory practices and quality system regulations, as applicable,
promulgated by the FDA. 
 “Code” means the United States Internal Revenue Code of 1986, as amended and the Treasury
regulations promulgated thereunder. 
 “COGs” means, with respect to Product, actual costs and expenses incurred or
accounted for by Alvogen or its Affiliates allocable to the sourcing and manufacture of Product (and the components thereof including the Drug Substance); provided, however with respect to Product (and the components thereof including the Drug
Substance) acquired by Alvogen or its Affiliates from a Third Party, the COGs for such Product (and the components thereof including the Drug Substance) shall be deemed to be the amount actually paid therefor to such Third Party or incurred by
Alvogen or its Affiliates for such Product (and the components thereof including the Drug Substance), including the transfer price payable by Alvogen or its Affiliate to a Third Party Supplier, and all out-of-pocket costs incurred by Alvogen (or its Affiliate) for handling, intake testing, and holding and storing of Product, including any special packaging expenses, Taxes, inspection fees and other similar out-of-pocket charges applicable to the shipping and transport of Product purchased by Alvogen or its Affiliate, in all cases for or allocable to Product in accordance with
Accounting Standards. 
 “Commercialization” means, with respect to a product, any and all processes and activities
conducted to establish and maintain sales for such product, including obtaining and maintaining pricing, reimbursement, coding and patient access, offering for sale, detailing, selling (including launching), marketing (including pre-launch and launch, as well as advertising activities), promoting, storing, transporting, distributing, and importing such product. For clarity, Commercialization includes activities traditionally conducted by
sales representatives (including field sales, institutional sales, pharmacy/trade sales and managed care sales representatives) and other individuals having similar functions. “Commercialize,” “Commercialized” and
“Commercializing” shall have their correlative meanings. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

3 

 “Competing Product” means (a) the Reference Product, (b) a
therapeutic product other than the Product that contains the active pharmaceutical ingredient of the Reference Product (including the Drug Substance or a modified or derivative version thereof) as its sole active pharmaceutical ingredient or
(c) any revised formulation, strength, presentation or delivery method of any product described in (a) or (b), where the Regulatory Materials with respect thereto reference or would be required to reference the Reference Product. 

“Control” means, with respect to particular Know-How or a particular Patent,
possession of the power and authority by the Party granting the applicable right, license or sublicense to the other Party as provided herein, whether arising by ownership, license, or other authorization, to disclose and deliver the particular Know-How to the other Party, or to grant and authorize under such Know-How or Patent the right, license or sublicense, as applicable, of the scope granted to such other Party
in this Agreement without giving rise to a violation of the terms of any agreement or other arrangement with, or the rights of, any Third Party. Notwithstanding anything to the contrary in this Agreement, the following shall not be deemed to be
Controlled by Pfenex: (a) any Know-How or Patent owned by or licensed to any Acquiring Entity (other than from Pfenex or its Affiliates) immediately prior to the effective date of the Acquisition
Transaction, and (b) any Know-How or Patent that any Acquiring Entity subsequently develops, which is not based upon and without accessing or practicing any
Know-How or Patent owned by or licensed to Pfenex immediately prior to the effective date of the Acquisition Transaction. “Controls” and “Controlled” have their correlative
meanings. 
 “Debarred Entity” means a Person (other than an individual) that has been debarred by the FDA pursuant
to 21 U.S.C. § 335a (a) or (b). 
 “Debarred Individual” means an individual who has been debarred by
the FDA pursuant to 21 U.S.C. § 335a (a) or (b). 
 “Diligent Efforts” means, with respect to the activities
to be conducted by a Party with respect to any objective, the reasonable, diligent, good faith efforts and resources (financial and otherwise) to accomplish such objective as similarly situated Third Parties would normally use to accomplish a
similar objective under similar circumstances, it being understood and agreed that, with respect to the development and commercialization of Product, such efforts shall be consistent with those efforts and resources similarly situated Third Parties
commonly expend for their own products (and, if the FDA has given notice that the Product is Therapeutically Equivalent to the Reference Product, for their own high-priority products) at a similar stage of development or commercialization and with
similar commercial and market potential. In considering Product’s commercial potential Alvogen shall not consider payments required to be paid to Pfenex hereunder. Without limiting the foregoing, such efforts shall include: (a) assigning
responsibilities for activities for which such Party is responsible to specific employee(s) who are held accountable for the progress, monitoring and completion of such activities in a timely manner, (b) setting and seeking to reasonably
achieve meaningful objectives for carrying out such activities, and (c) making and implementing reasonable decisions and allocating resources reasonably necessary or appropriate to advance progress with respect to and complete such
objectives in an expeditious manner, in each case, consistent with the efforts and resources normally used by similarly situated Third Parties in the performance of 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

4 

 
such activity for their own products (and, if the FDA has given notice that the Product is Therapeutically Equivalent to the Reference Product, for their own high-priority products), in each case
owned by such Party or to which such Party has exclusive rights, at a similar stage of development or commercialization and with similar commercial and market potential as Product, taking into account all relevant factors, including patent coverage,
safety and efficacy, product profile, competitiveness of the marketplace and other products, proprietary position and profitability (including pricing and reimbursement). 

“Distribution Cost Allowance” means, for each Quarterly Period, an expense allowance [***] for [***]. 

“Dow Technology Assignment Agreement” means that certain Technology Assignment Agreement, dated as of
November 30, 2009, by and between Dow Global Technologies Inc., The Dow Chemical Company and Pfenex. 
 “Dow Technology
Licensing Agreement” means that certain Technology Licensing Agreement, dated as of November 30, 2009, by and between Dow Global Technologies Inc., The Dow Chemical Company and Pfenex. 

“Drug Substance” means that certain peptide as described in more detail in the Product Memo. 

“FATCA” means Sections 1471 through 1474 of the Code, as of the date of this Agreement (or any amended or successor version
that is substantively comparable and not materially more onerous to comply with), any current or future regulations or official interpretations thereof, any agreement entered into pursuant to Section 1471(b)(1) of the Code (or any amended or
successor version described above), and any intergovernmental agreement entered into in connection with the implementation of such Sections of the Code and any fiscal or regulatory legislation, rules or practices adopted pursuant to such
intergovernmental agreement. 
 “FDA” means the United States Food and Drug Administration, or any successor agency
thereto. 
 “First Commercial Sale” means the first commercial sale of Product to a Third Party by or under
authority of Alvogen or any of its Affiliates or approved sublicensees in the Territory after NDA Approval for Product. 
 “Freight
Charges” means out-of-pocket freight, shipping and insurance costs, as well as any special packaging expenses, Taxes, inspection fees and other out-of-pocket charges incurred by Alvogen (or its Affiliate), to the extent attributable to the shipping and transport of Product from the Third Party Supplier to Alvogen (or
its Affiliate) in accordance with Accounting Standards. 
 “Governmental Authority” means any supranational,
national, regional, state, provincial, local or other government, or other court of competent jurisdiction, legislature, governmental, administrative or regulatory agency, department, body, bureau, council or

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

5 

 
commission or any other supranational, national, regional, state, provincial, local or other governmental authority or instrumentality, including the FDA, in each case having jurisdiction in any
country or other jurisdiction. 
 “Gross Profit” means, with respect to a particular Quarterly Period, the amount
equal to Net Sales during such Quarterly Period less [***], to the extent attributable or allocated to the sale of Product; provided, however, that in the event that Gross Profit is negative during any Quarterly Period, such negative amount will be
carried forward to future Quarterly Periods for the purpose of calculating Gross Profit. Any negative amounts will be carried forward until such negative amounts are completely offset by Gross Profit from future Quarterly Periods. 

“Indemnified Taxes” means Taxes imposed as a result of any assignment or other transfer of any kind of any rights
under this Agreement by any Party to any Assignee (including by merger, liquidation or reorganization) on the other Party (the “Non-Assigning Party”), or on any payment by the Assignee under
this Agreement to the Non-Assigning Party, other than Taxes imposed on or with respect to the Non-Assigning Party or required to be withheld or deducted from a payment
to the Non-Assigning Party that are (a) imposed on or measured by net income (however denominated), franchise Taxes, and branch profits Taxes, in each case (i) imposed as a result of the Non-Assigning Party being organized under the laws of, or having its principal office in, the jurisdiction imposing such Taxes (or any political subdivision thereof), or (ii) that are imposed as a result of a
present or former connection between the Non-Assigning Party and the jurisdiction imposing such Tax (other than connections arising from the Non-Assigning Party having
executed, delivered, become a party to, performed its obligations under, received payments under, received or perfected a security interest under, engaged in any other transaction pursuant to or enforced this Agreement), (b) attributable to the
Non-Assigning Party’s failure to comply with Section 8.5(a), and (c) any withholding Taxes imposed under FATCA. The term Indemnified Taxes includes penalties, fines and other additional
statutory charges incidental or related to the imposition thereof, only to the extent not caused by the acts or omissions of the Non-Assigning Party. 

“Intellectual Property” means any and all intellectual property or intangible rights anywhere in the world, including
(a) Patents, (b) published and unpublished works of authorship, whether copyrightable or not, including all statutory and common law copyrights associated therewith, (c) trade secrets, and
(d) Know-How, but excluding Trademarks. 

“Know-How” means technical information and materials, in any tangible or
intangible form whatsoever, including technology, reports, databases, data, results, analytical models, chemicals, inventions (patentable or otherwise), practices, methods, knowledge, techniques, specifications, formulations, formulae, know-how, skill, experience, test data, including pharmacological, biological, chemical, biochemical, toxicological and clinical test data, analytical and quality control data, stability data, studies and procedures
and patent and other legal information or descriptions; provided, however, that Know-How shall exclude any Patents. 

“Lien” means any liens, claims, charges, pledges, security interests or other encumbrances of any nature whatsoever.

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

6 

 “Manufacturing Cost” means, with respect to a particular Quarterly Period,
means the quotient of (a) the COGs for all Product sold during such Quarterly Period, divided by (b) the total number of units of Product sold during such Quarterly Period. 

“NDA” means a New Drug Application filed with the FDA as more fully defined in 21 C.F.R. §314.50 et. seq.
(including any such application filed pursuant to Section 505(b)(1) or Section 505(b)(2)). 
 “NDA Approval”
means, with respect to a pharmaceutical product in the Territory, approval by the FDA of the initial NDA therefor. 
 “Net
Sales” means, for a specified period, the gross revenue recognized by Alvogen or its Affiliates or its approved sublicensees (any, a “Selling Person”) for the commercial sale of Product by a Selling Person to Third
Parties, less the following deductions to the extent charged as part of the invoiced price, separately stated on the invoice, calculated as a function of the invoice price or otherwise taken, paid, accrued, allowed, included or allocated (without
duplication, and to the extent not reimbursed by a Third Party): 
 (a)    [***]; 

(b)    [***]; 

(c)    [***]; 

(d)    [***]; 

(e)    [***]; 

(f)    [***]; and 

(g)    [***]; 
 in each case
(a) – (g), [***]. 
 Notwithstanding the foregoing, sales among Selling Persons shall not be included in the computation of Net
Sales hereunder (except where such Selling Person is an end user). 
 For clarity, any Product that is provided for use as promotional
samples or in connection with a compassionate use program shall be excluded from the calculation of Net Sales, is not a “commercial sale” for purposes of this Agreement and shall not be taken into account in determining Average Sale Price.

 In the case of any sale or transfer of a Product to a non-Affiliate other than in a transaction
exclusively for cash, the Net Sales amount per unit shall be deemed to be the Average Sale Price for the calendar quarter in which such sale or transfer took place. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

7 

 With respect to a Bundled Product, the Net Sales of such Bundled Product shall first be
calculated in accordance with the definition of Net Sales above, and then the Net Sales of Product included in such Bundled Product shall be determined as follows: 

(i)    [***]; or 

(ii)    [***]. 

“Orange Book” means the FDA publication Approved Drug Products with Therapeutic Equivalence Evaluations, as may be
amended from time to time. 
 “Patent” means (a) any issued patent, including any inventor’s certificate,
substitution, extension, confirmation, reissue, reexamination, renewal or any like governmental grant for protection of inventions, and (b) any pending application for any of the foregoing, including any continuation, divisional, substitution, continuation-in-part, provisional and converted provisional application. 

“PDUFA Fee” means the fee payable to the FDA pursuant 21 U.S.C. 379h for the review of the initial NDA filed with
respect to the Product. 
 “Person” means an individual, a partnership, a limited liability company, a corporation,
an association, a joint stock company, a trust, a joint venture, an unincorporated organization, a Governmental Authority or other entity of any kind. 

“Pfenex Expression Technology” means Pfenex’s proprietary Pseudomonas fluorescens expression platform
technology used in the development and production of strains to produce biologic and other pharmaceutical products (including the Product) through the optimization of a nucleic acid sequence, together with all Intellectual Property related thereto,
including all other Intellectual Property (including Patents and Know-How) transferred or licensed to Pfenex under the Dow Technology Assignment Agreement or the Dow Technology Licensing Agreement. 

“Pfenex Know-How” means Know-How
Controlled by Pfenex or its Affiliates at any time during the Term that is necessary or used for the operation of the Business in the Territory. 

“Pfenex Patents” means Patents in the Territory Controlled by Pfenex or its Affiliates at any time during the Term
(a) claiming the composition of the Drug Substance (and Product), (b) claiming methods of use, administration or formulation of the Drug Substance (and Product), or (c) claiming the manufacture of the Drug Substance. A list of current
Pfenex Patents is set forth in the Product Memo. 
 “Pfenex Technology” means, collectively, the Pfenex Know-How, the Pfenex Patents and the Product Inventions, but excluding the Pfenex Expression Technology. 

“Pfenex’s Knowledge” means the actual knowledge, after reasonable inquiry, of Pfenex’s Chief Executive
Officer, Chief Financial Officer, Chief Business Officer, and Pfenex’s Senior Director of Upstream Processing and Intellectual Property. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

8 

 “Prior Agreements” means (a) that certain Letter of Intent
between the Alvogen Group, Inc. and Pfenex dated May 25, 2018, and (b) that Secrecy Agreement between the Alvogen Group, Inc. and Pfenex dated September 1, 2017. 

“Product” means pharmaceutical product consisting of the Drug Substance as the sole active pharmaceutical ingredient
as further described in the Product Memo; “Product”, when referring to a manufactured product, means such product on final packaged form and meeting the specifications therefor. 

“Product Documentation” means all marketing and promotional literature, packaging inserts (including patient
information leaflets) and customer documentation applicable to Product. 
 “Product Memo” means that certain memorandum
exchanged between the Parties on the Effective Date and referencing this Agreement. 
 “Product Trademark” means the
Trademark set forth in the Product Memo, or such other Trademark as designated pursuant to Section 6.1(b). 
 “Prosecution and
Maintenance” means, with regard to a Patent, the preparation, filing, prosecution and maintenance of such Patent, as well as re-examinations, reissues, requests for Patent term extensions and
the like with respect to such Patent, together with the conduct of interferences and inter partes actions, the defense of oppositions and other similar proceedings with respect to the particular Patent; and “Prosecute and Maintain”
has its correlative meaning. 
 “Quarterly Period” means a three (3) month period of each calendar year ending
on March 31, June 30, September 30 or December 31, except that the first Quarterly Period shall be a period commencing on the Effective Date and ending on September 30, 2018. 

“Reference Product” means Forteo® (teriparatide), as branded
and approved in the Territory. 
 “Registrations” means all permits, licenses, approvals and authorizations granted
by any Regulatory Agency with respect to Product (including the manufacture, handling, storage, import, transport, distribution, marketing, promotion, advertising or sale thereof). 

“Regulatory Agency” mean any federal, state or local regulatory agency, department, bureau or other Governmental Authority in
the United States, the European Union or any other country, as applicable, including the FDA in each case that is responsible for Registrations necessary for, or otherwise governs, the manufacture, handling, storage, import, transport, distribution
or sale of Product. 
 “Regulatory Approval” means, with respect to Product in a given country, all necessary
Registrations from the applicable Regulatory Agency in such country to distribute, market, promote, sell and place on the market Product in such country. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

9 

 “Regulatory Commitment Activities” means any study or trial of
Product that is required by the FDA to be conducted after NDA Approval, or that the sponsor of the NDA agrees at the written request of FDA will be conducted following such approval. 

“Regulatory Materials” means, with respect to a product, regulatory applications (including NDAs), submissions,
notices, notifications, communications, correspondence, Registrations or other filings (including requests for Therapeutic Equivalence designation) made to, received from or otherwise conducted with any Regulatory Agency (including minutes of
meetings with any Regulatory Agency) that are necessary for or otherwise relate to the development, manufacture or Commercialization of such product. 

“Safety Reasons” means it is a Party’s reasonable belief that there is an unacceptable risk for harm in humans
based upon (a) preclinical safety data, including data from animal toxicology studies, or (b) the observation of serious adverse effects in humans after Product has been administered to humans, such as during a clinical study or after the
First Commercial Sale, in each of clauses (a) and (b), which would materially impact the safety or efficacy and the commercial feasibility of Product. 

“Tax” or “Taxes” means any and all taxes, including value added taxes, duties, imposts,
charges, withholdings, rates, levies and other governmental impositions and other taxes of any kind whatsoever imposed, assessed or charged. 

“Taxing Authority” means any Governmental Authority responsible for the imposition, assessment or collection of any
Tax, including the United States Internal Revenue Service. 
 “Territory” means the United States of America,
including the District of Columbia, the Commonwealth of Puerto Rico and all other territories and possessions of the United States of America (collectively, the “United States” or “U.S.”). 

“Therapeutically Equivalent” or “Therapeutic Equivalence” means, with respect to a pharmaceutical product,
that such pharmaceutical product is “therapeutically equivalent” to a designated reference product, as defined in the Preface to the current edition of the Orange Book, such that the applicable pharmaceutical product would be substitutable
by a pharmacist for the designated reference product when filling a prescription written for such reference product without having to seek authorization to do so from the physician writing such prescription (i.e., an
A-Rated product). 
 “Third Party” means any Person other than a Party and
such Party’s Affiliates. 
 “Trademark” means, any trademark, service mark, trade dress, trade name, assumed name and
entity name, together with the goodwill associated with and symbolized by such trademark, service mark, trade dress, trade name and entity name, in each case whether or not registered. 

Section 1.2    Additional Definitions. Each of the following terms has the meaning defined in the
corresponding Section or part of the Agreement indicated below: 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

10 

							
	 Defined Term
	 	 Section
	 	 Defined Term
	 	 Section

	ADR	 	Exhibit 12.5	 	Neutral	 	Exhibit 12.5
	Agents	 	Section 8.2	 	Other Party	 	Section 3.3(a)
	Agreement	 	Preamble	 	Parties	 	Preamble
	Alvogen	 	Preamble	 	Party	 	Preamble
	Alvogen Indemnitees	 	Section 11.1	 	Pfenex	 	Preamble
	Article III Activities	 	Section 3.3(a)	 	Pfenex Housemark	 	Section 6.1(d)
	Assisting Party	 	Section 3.4(e)	 	Pfenex Indemnitees	 	Section 11.2
	Bankruptcy Code	 	Section 12.15	 	Pfenex Profit Share	 	Section 4.5
	COGs Reduction Plan	 	Section 5.2(a)	 	Product Financial Records	 	Section 4.8
	Commercial Territory	 	Section 5.8(a)	 	Product Inventions	 	Section 6.2
	Commitment Activities	 	Section 3.2(b)	 	Product License	 	Section 2.1
	Common Interest Agreement	 	Section 6.9	 	Product Records	 	Section 3.3(d)
	Confidential Information	 	Section 8.1	 	PTO	 	Section 6.3(a)
	Confidentiality Exceptions	 	Section 8.1	 	PV Agreement	 	Section 3.3(e)
	Cooperating Party	 	Section 6.5(d)	 	Regulatory Commitment Costs	 	Section 3.2(c)
	Development Plan	 	Section 3.1(a)	 	Responsible Party	 	Section 3.3(a)
	Dispute	 	Section 12.4	 	Reviewing Party	 	Section 3.4(a)
	Effective Date	 	Preamble	 	SEC	 	Section 8.7
	Enforcement Action	 	Section 6.5(b)	 	Solicitation Action	 	Section 8.6
	Enforcing Party	 	Section 6.5(d)	 	Soliciting Party	 	Section 8.6
	Executive Steering Committee	 	Section 7.1	 	Subcontractor	 	Section 3.3(c)
	Filing Party	 	Section 3.4(a)	 	Taxed Party	 	Section 8.5(c)
	Force Majeure	 	Section 12.1	 	Term	 	Section 10.1
	Indemnification Notice	 	Section 11.3(a)	 	Territory Medical Affairs Strategy	 	Section 3.2(b)(ii)
	Indemnification Objection	 	Section 11.3(b)	 	Third Party Action	 	Section 6.4(a)
	Indemnified Party	 	Section 11.3(a)	 	Third Party Claim	 	Section 11.1
	Indemnify	 	Section 11.1	 	Third Party Supplier	 	Section 5.1(a)
	Indemnifying 	 	Section 11.3(a)	 	Trademark 	 	Section 6.1(a)

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

11 

							
	 Defined Term
	 	 Section
	 	 Defined Term
	 	 Section

	Party	 		 	License	 	
	Infringement Notice	 	Section 6.5(a)	 	Transfer Effective Date	 	Section 3.2(a)
	Infringing Activity	 	Section 6.5(a)	 	Transfer Taxes	 	Section 8.5(d)
	IP Strategy	 	Section 7.1	 	Working Committee	 	Section 7.1
	Losses	 	Section 11.1	 		 	

 Section 1.3    Interpretation. Interpretation of this Agreement is governed by
the following rules of construction, unless the context clearly requires otherwise: (a) words in the singular include the plural and vice versa, and words of one gender shall be held to include the other gender as the context requires;
(b) references to the terms article, section, paragraph and exhibit are references to the Articles, Sections, Paragraphs and Exhibits to this Agreement; (c) references to “$” and “Dollars” mean United States dollars;
(d) the words “including,” “includes,” and words of similar meaning are interpreted as incorporating the phrase “without limitation,” or “but not limited to”; (e) the word “or” have the meaning
associated with the phrase “and/or” and not be exclusive; (f) provisions apply, when appropriate, to successive events and transactions; (g) a reference to any Person includes such Person’s successors and permitted assigns;
(h) this Agreement is construed without regard to any presumption or rule requiring construction or interpretation against the Party drafting or causing any instrument to be drafted; (i) the word “day” means a calendar day unless
otherwise specified; (j) the word “notice” means notice in writing (whether or not specifically stated) and shall include notices, consents, approvals and other communications contemplated under this Agreement; (k) each
accounting term not otherwise defined in this Agreement has the meaning assigned to it consistent with the requirements of Accounting Standards; (l) the words “hereof,” “herein,” “hereby,” “hereunder” and
derivative or similar words refer to this Agreement (including the Exhibits); (m) provisions that require that a Party, the Parties or the Executive Steering Committee “agree,” “consent” or “approve” or the like require
that such agreement, consent or approval be specific and in writing, whether by written agreement, letter, approved minutes or otherwise; (n) references to any specific law, rule or regulation, or article, section or other division thereof,
shall be deemed to include the then-current amendments thereto or any replacement law, rule or regulation thereof; and (o) neither Party or its Affiliates shall be deemed to be acting “on behalf of” the other Party hereunder. All
Exhibits referred to herein are hereby incorporated by reference. The headings contained in this Agreement are used only as a matter of convenience, and in no way define, limit, construe or describe the scope or intent of any Section of this
Agreement. When calculating any cost, expense or other amount hereunder no specific charge or element thereof shall be accounted for more than once. 

ARTICLE II 
 GRANT OF
LICENSE 
 Section 2.1    Product License. Subject to the terms and conditions of this Agreement, Pfenex
hereby grants to Alvogen (a) an exclusive license under the Pfenex Technology to Commercialize Product in the Territory during the Term, and (b) an exclusive license under the 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

12 

 
Pfenex Technology to (i) manufacture or have manufactured the Product (and components thereof including the Drug Substance) in the Territory during the Term, and (ii) conduct any
development activities assigned to Alvogen under the Development Plan in the Territory with respect to Product during the Term (collectively, the “Product License”). The Product License shall be transferable solely in
accordance with Section 12.7 and sublicensable solely in accordance with Section 2.2. 

Section 2.2    Sublicenses. 

(a)    The Product License includes the right to sublicense within the scope thereof; provided, however, that Alvogen shall
not sublicense to a Third Party its license under the Pfenex Technology to Commercialize, or have manufactured, Product in the Territory except (i) to a Third Party Supplier, (ii) as reasonably necessary to comply with Applicable Law, or
(iii) as mutually agreed by the Parties in writing. For clarity, it is understood and agreed that, Alvogen may use distributors in the Territory, provided that (A) Alvogen remains responsible to ensure that the activities of any such
distributors are consistent with the terms of this Agreement, and (B) Alvogen (or its Affiliate) (I) books sales of Product in the Territory in accordance with Alvogen’s ordinary course of business, and (II) remains primarily
responsible for the marketing and promotion of Product in the Territory, which will be under the Product Trademark or other trademarks Controlled by Alvogen or its Affiliates. 

(b)    Alvogen shall obtain Pfenex’s written approval prior to the grant of any sublicense and provide Pfenex a copy
of the final executed sublicense agreement. 
 (c)    Alvogen shall be responsible for the failure by its sublicensees
to comply with all relevant restrictions, limitations and obligations in this Agreement. 
 (d)    Alvogen shall also
have the right to sublicense the Trademark License granted pursuant to Section 6.1(a), provided that such sublicense shall be (i) granted to the applicable approved sublicensee in conjunction with a sublicense under the Product License
granted pursuant to this Section 2.2, and (ii) subject to the terms and conditions of this Section 2.2. 

Section 2.3    No Implied Licenses; Retained Rights. Each Party acknowledges that the rights and licenses
granted under this Article II and elsewhere in this Agreement are limited to the scope expressly granted. Accordingly, except for the rights expressly granted under this Agreement, no right, title, or interest of any nature whatsoever is granted
whether by implication, estoppel, reliance or otherwise, by either Party to the other Party. Without limiting the obligations hereunder (including the exclusivity set forth in Section 2.4), all rights with respect to Know-How, Patents or other Intellectual Property that are not specifically granted herein are reserved to the owner thereof, and specifically, Pfenex retains all rights under the Pfenex Technology to
(a) Commercialize, Product outside the Territory, (b) conduct development activities with respect to Product (and components thereof including the Drug Substance) worldwide, solely to support development and Commercialization of Product
outside the Territory and (c) engage and authorize Third Parties to conduct the activities described in clauses (a) and (b). Alvogen agrees that it will not, and it will ensure that its Affiliates will not, and it

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

13 

 
will not grant any sublicensee the right to, use or otherwise exploit the Pfenex Technology, except as expressly licensed and permitted in this Agreement. 

Section 2.4    Non-Competition. Neither Party nor their respective
Affiliates shall, directly or indirectly, itself, through an Affiliate or otherwise, (a) research, develop, seek or obtain NDA Approval or any other Regulatory Approval in the Territory for (or take any actions directed thereto), manufacture,
market, import, offer for sale, sell or otherwise Commercialize (including through a distributor or other Third Party) any Competing Product in the Territory during the Term or (b) authorize or assist (including by investing in or otherwise
providing funding to) any Third Party to do any of the foregoing. 
 ARTICLE III 

DEVELOPMENT / REGULATORY ACTIVITIES 

Section 3.1    Pfenex Responsibilities. Pfenex (itself or, subject to Section 3.3, through its Affiliates
or Third Parties) shall use Diligent Efforts to: 
 (a)    conduct the development activities for Product in the
Territory set forth in the development plan and associated timelines attached hereto as Exhibit 3.1(a) (as may be updated by the Executive Steering Committee, the “Development Plan”) and such activities
shall be conducted in accordance with applicable cGxP and Applicable Law with the goal of supporting the preparation and filing of an NDA for the Product and obtaining NDA Approval for the Product; 

(b)    prepare, file with the FDA and defend the NDA for Product and obtain NDA Approval for Product. In connection with
the filing and review of such NDA, Pfenex shall apply for and use Diligent Efforts to obtain a waiver (or reduction) with respect to the PDUFA Fee, as provided in 21 U.S.C. 379h(d); provided, however, if despite such Diligent Efforts, the FDA
notifies Pfenex that any PDUFA Fee is payable, then the Parties shall share the cost of such PDUFA Fee equally (i.e., on a 50:50 basis). Accordingly, Alvogen shall remit its share of the PDUFA Fee to Pfenex within five (5) Business Days of
receipt of an invoice therefor from Pfenex; and 
 (c)    Upon receipt of NDA Approval for Product, Pfenex shall file a
notice with the FDA (and copying Alvogen) under 21 CFR 314.72 transferring the NDA Approval to Alvogen (the “Transfer Notice”). 

Section 3.2    Alvogen Responsibilities. 

(a)    Upon receipt of the Transfer Notice, Alvogen shall file a notice with the FDA (and copying Pfenex) under 21 C.F.R.
314.72 accepting transfer of the NDA Approval and specifying the date that the change in ownership is effective (the “Transfer Effective Date”). 

(b)    As of the Transfer Effective Date, Alvogen shall: 

(i)    be responsible for and conduct (itself or, subject to Section 3.3(c), through its Affiliates or Third
Parties) (A) all Regulatory Commitment Activities and post-

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

14 

 
marketing surveillance studies and data collection and analysis with respect to Product in the Territory; (B) all pharmacovigilance activities with respect to Product in the Territory
(subject to the PV Agreement); and (C) all medical investigations and evaluations and the reporting of Adverse Drug Responses related to Product in the Territory, in each case (clauses (A) – (C)) as required by the FDA or under
Applicable Law (collectively, the “Commitment Activities”); 
 (ii)    have the exclusive right to
control, and shall use Diligent Efforts to conduct, a comprehensive strategy of all medical affairs matters relating to Product in the Territory (the “Territory Medical Affairs Strategy”), including with respect to (i) the
preparation of any publication based on data and other information relating to any trial or study with respect to Product in the Territory, or (ii) the planning and implementation of congress participations, medical education programs and key
opinion leader or advisory board meetings with respect to Product in the Territory; and 
 (iii)    use Diligent
Efforts to take such other actions reasonably necessary to maintain the NDA Approval for Product. 
 (c)    Alvogen
shall bear all costs and expenses in connection with Alvogen’s responsibilities under this Section 3.2 (the “Regulatory Commitment Costs”), including the costs and expenses incurred in connection with the Commitment
Activities and the Territory Medical Affairs Strategy; provided that Pfenex may, at its sole discretion, elect to reimburse Alvogen for any portion of such Regulatory Commitment Costs, and any such reimbursed amounts shall not be counted toward the
amounts described in Section 10.2(b)(v). 
 Section 3.3    Coordination; Assistance; Subcontracting.

 (a)    The Party responsible for conducting a particular activity pursuant to this Article III (with respect to such
activity, the “Responsible Party”) shall keep the other Party (the “Other Party”) reasonably informed as to the Responsible Party’s (and its Affiliates’) planned activities (including written plans with
estimated timelines) and progress with respect to such activities (individually and collectively, the “Article III Activities”) through quarterly updates to the Executive Steering Committee. 

(b)    The Other Party shall cooperate and provide the Responsible Party with reasonable assistance in connection with the
performance by the Responsible Party of its Article III Activities. 
 (c)    The Responsible Party may subcontract to
Affiliates or Third Parties (each, a “Subcontractor”) any portion of its responsibilities with respect to development of Product in the Territory. Each Subcontractor shall enter into a written agreement with the Responsible Party
pursuant to which such Subcontractor shall (i) be bound by obligations of confidentiality and non-use with respect to the Confidential Information of the Other Party or otherwise relating to Product at
least as protective as the obligations set forth in Section 8.1 through Section 8.3, (ii) be bound by obligations with respect to Intellectual Property sufficient to enable the Responsible Party to comply with the terms and conditions
of this Agreement as if the Responsible Party completed any such subcontracted Article III Activity itself, (iii) be required to make representations and warranties with respect to debarment comparable to the

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

15 

 
representations and warranties made by the Responsible Party under Section 9.2(g), (iv) be obligated to provide notice to the Responsible Party upon becoming the subject of any
investigation or debarment proceeding that could lead to such Subcontractor becoming a Debarred Entity or Debarred Individual, and (v) be required to comply with all Applicable Laws, including, if applicable, cGxP. The Responsible Party shall
supervise and be responsible under this Agreement for the work of any such Subcontractor. No subcontracting of any obligation or activity under this Agreement shall relieve the Responsible Party of any of its obligations or responsibilities under
this Agreement. 
 (d)    The Responsible Party shall, and shall cause each Subcontractor engaged pursuant to
Section 3.3(c) to, maintain complete and accurate books and records, in sufficient detail (and in good scientific manner appropriate for patent and regulatory purposes, when applicable, and in compliance with all Applicable Laws) and for
purposes of demonstrating compliance with the terms hereof, that fully and properly reflect all work done and results achieved with respect to development of Product in the Territory (the “Product Records”). The Responsible Party
shall retain all Product Records for a period of at least three (3) years or for such longer period to the extent required by Applicable Law. During such period, upon the written request of the Other Party, the Product Records shall be subject
to inspection and audit by and at the expense of the Other Party no more than two times in any Annual Period. Such audits shall occur upon reasonable notice and during normal business hours by an independent auditor selected by the Other Party and
reasonably acceptable to the Responsible Party. The Other Party shall treat all information received or subject to review under this Section 3.3(d) as Confidential Information of the Responsible Party in accordance with the provisions of
Article VIII. The Other Party shall cause its independent auditor to enter into a confidentiality agreement, in form and substance reasonably acceptable to the Responsible Party, to maintain such records and information of the Responsible Party in
confidence in accordance with Article VIII and not use such records or information except to the extent permitted by this Agreement, including any enforcement of the provisions hereof. 

(e)    The Parties shall enter into one or more safety exchange or pharmaco-vigilance agreements (each, a “PV
Agreement”) on reasonable and customary terms to ensure compliance with safety reporting requirements of all applicable Regulatory Agencies globally (including in connection with maintaining the NDA Approval for Product) by providing
detailed procedures regarding the collection, exchange and management of safety data relating to Product, including but not limited to the establishment and maintenance of a global safety database (which database shall be maintained by Alvogen),
Adverse Drug Responses collection and reporting, and maintenance of core safety information. Pfenex (itself, its Affiliates and licensees) shall have reasonable access to such database and the data therein, including the right to query such data to
determine and report safety signals. 
 Section 3.4    Regulatory Materials. 

(a)    Prior to the Transfer Notice, Pfenex shall have the sole right to control filing or submission of Regulatory
Materials to the FDA with respect to the Product including the NDA for Product, subject to Section 3.1 and the oversight of and in consultation with the Executive Steering Committee, and shall be responsible for managing all communications and

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

16 

 
interactions with the FDA with respect to Product in the Territory. From and after the Transfer Notice, Alvogen shall have the sole right to control filing or submission of Regulatory Materials
with the FDA with respect to Product including the NDA Approval for Product, subject to Section 3.2 and the oversight of and in consultation with the Executive Steering Committee, and shall be responsible for managing all communications and
interactions with the FDA with respect to Product in the Territory. In either case, prior to the filing of any Regulatory Materials (including the NDA) for Product with the FDA, the filing Party (the “Filing Party”) shall provide a
copy thereof to the other Party (through the Executive Steering Committee, the “Reviewing Party”) for its review and comment. The Reviewing Party shall have fifteen (15) Business Days from the date it receives a copy of any
Regulatory Materials with respect to the Product to provide the Filing Party with comments regarding such Regulatory Materials, unless the FDA or Applicable Law requires that such Regulatory Material(s) be filed on a timeline that does not
reasonably permit such advanced notice, in which case the Reviewing Party shall have as much time as is reasonably practicable to provide the Filing Party with comments. The Filing Party shall consider all such comments in good faith. The Filing
Party shall, to the extent permitted by Applicable Law, provide the Reviewing Party with (i) reasonable advanced notice (and in no event less than fifteen (15) Business Days’ advance notice whenever feasible) of substantive meetings
with any Regulatory Agency in the Territory that are either scheduled with or initiated by or on behalf of the Filing Party or its Affiliates, (ii) an opportunity to have a reasonable number (but at least two (2)) representatives participate in
all substantive meetings with the FDA with respect to Product, and in any case keep the Reviewing Party informed as to all material interactions with the FDA with respect to Product, and (iii) a copy of any material documents, information and
correspondence submitted to or received from the FDA with respect to Product as soon as reasonably practicable. 

(b)    To the extent permitted by Applicable Law and necessary or useful to maintain the NDA Approval (including any
supplement thereto) for Product in the Territory, Alvogen shall have a right to refer to and use in any filing with respect to the NDA Approval for Product to the FDA, all (i) regulatory filings (including the NDA), (ii) NDA Approval, and
(iii) documents, information and data contained in such filings or approvals, which Pfenex has used or filed with or produced to the FDA with respect to Product or the Pfenex Technology. Pfenex shall submit and file with the FDA all documents
necessary or advisable to grant to Alvogen such rights to such filings, approvals, documents, information or data, subject in each case to the requirements and restrictions of the FDA. Alvogen may sublicense the right of reference set forth in this
Section 3.4(b) to its sublicensees for the Territory in accordance with Section 2.2. 
 (c)    To the extent
permitted by Applicable Law and necessary or useful to obtain or maintain any marketing or other approval or for the filing of any Regulatory Materials for Product for the development, manufacture, or Commercialization of Product outside the
Territory, Pfenex shall have a right to refer to and use in filing for such approvals with Regulatory Agencies outside the Territory, all (i) Regulatory Materials (including the NDA), (ii) NDA Approval, and (iii) documents,
information and data contained in such filings or approvals, which Alvogen has used or filed with or produced to the FDA with respect to Product or the Pfenex Technology. Alvogen shall submit and file with the applicable Regulatory Agency all
documents necessary or advisable to grant to Pfenex such rights to such materials, filings, 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

17 

 
approvals, documents, information or data, subject in each case to the requirements and restrictions of the applicable Regulatory Agency. Pfenex may sublicense the right of reference set forth in
this Section 3.4(c) to its licensees solely for use in connection with the development, manufacture, or Commercialization of Product outside the Territory. 

(d)    Each Party disclaims any representation or warranty that any filings, approvals, documents, information or data
provided as set forth in this Section 3.4 shall meet the requirements of any particular country, or that such filings, approvals, documents, information or data shall be adequate or usable by the other Party in connection with seeking any
marketing authorization for Product in any particular country. 
 (e)    Each Party (the “Assisting
Party”) shall cooperate and provide the other Party with reasonable assistance in connection with the exercise by the other Party of its rights and performance by the other Party of its obligations under this Article III and, in connection
therewith, the Assisting Party shall provide to the other Party all Product dossiers and other information that are in the Assisting Party’s possession or control (in such form as maintained by or on behalf of the Assisting Party in the
ordinary course of business, and without obligation to provide any translations) and reasonably requested by the Other Party for purposes of performing such obligations or exercising such rights with respect to the Product, and the other Party shall
be entitled to use such dossiers and other information for such purpose. 
 ARTICLE IV 

PAYMENTS 

Section 4.1    Upfront License Payment. In partial consideration of Alvogen’s rights under this
Agreement, Alvogen shall pay to Pfenex a one-time upfront license payment in the amount of Two Million Five Hundred Thousand Dollars ($2,500,000), such amount to be paid within 3 Business Days of the Effective
Date. Such upfront license payment shall be non-refundable and non-creditable. 

Section 4.2    Support Payments. 

(a)    On the later to occur of (a) October 31, 2018 and (b) within thirty (30) days of Alvogen’s
receipt from Pfenex of copy of the notice from the FDA that FDA has accepted the NDA for Product for review, Alvogen shall pay to Pfenex a one-time support payment in the amount of Two Million Five Hundred
Thousand Dollars ($2,500,000), in consideration of Pfenex’s production of consistency batches of Product and related development and support activities. Such support payment shall be non-refundable and non-creditable, provided that, for the avoidance of doubt, all tangible materials arising from such consistency batches shall be owned by Alvogen. 

(b)    Alvogen agrees to either, at its option: (i) reimburse Pfenex for its reasonable, out-of-pocket expenses approved in advance by Alvogen (which approval will not be unreasonably withhold, conditioned or delayed) incurred from and after June 1, 2018 with
respect to Third Party consultant/contractors engaged by Pfenex as of the Effective Date with respect to regulatory affairs, quality, manufacturing and supply chain for the Product (the 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

18 

 
“Product Contractors”) or (ii) provide, at Alvogen’s cost, internal or external experts (reasonably acceptable to Pfenex) to provide the support equivalent to Product
Contractors. 
 Section 4.3    Approval Payment. Within [***] of Alvogen’s receipt from Pfenex of a
copy of the notice NDA Approval for Product, Alvogen shall pay to Pfenex [***]. 

Section 4.4    Therapeutically Equivalent Milestone Payment. In further consideration of Alvogen’s rights
under this Agreement, Alvogen shall pay to Pfenex [***] within [***] of receipt of notice from the FDA that the Product is Therapeutically Equivalent to the Reference Product [***]: 

 

			
	 [***]
	  	[***]
		
	 [***]
	  	[***]
		
	 [***]
	  	[***]
		
	 [***]
	  	[***]

 Such milestone payment shall be non-refundable and
non-creditable. 
 Section 4.5    Profit Share. Commencing on the
First Commercial Sale in the Territory and continuing so long as there are Net Sales of Product in the Territory, Alvogen shall pay to Pfenex a share of Gross Profit for each Quarterly Period in an amount equal to the following (such percentage
share paid to Pfenex, the “Pfenex Profit Share”): 
 (a)    For each Quarterly Period that begins prior
to receipt of notice from the FDA that the Product is Therapeutically Equivalent to the Reference Product, the percentage of Gross Profit during such Quarterly Period (“Quarterly Gross Profits”) as set forth in the table immediately
below: 
  

			
	 Amount of Quarterly Gross Profits
	  	Percentage payable to Pfenex
	 [***]
	  	[***]
		
	 [***]
	  	[***]
		
	 [***]
	  	[***]

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

19 

 (b)    For each Quarterly Period that begins on or after receipt of
notice from the FDA that the Product is Therapeutically Equivalent to the Reference Product, [***] of Quarterly Gross Profits of Product in the Territory. 

(c)    Within sixty (60) days following the end of each Quarterly Period following the First Commercial Sale, Alvogen
shall pay to Pfenex all amounts payable pursuant to this Section 4.5 by wire transfer of immediately available funds to the account designated by Pfenex. 

Section 4.6    Reports. With respect to every Quarterly Period for which Alvogen is obligated to make any
payments under Section 4.5, Alvogen shall furnish to Pfenex a written report for such Quarterly Period within thirty (30) days after the end of such Quarterly Period showing in reasonably specific detail: 

(a)    the total gross amounts invoiced for Product sold by all Selling Persons and the calculation of Net Sales for
Product during such Quarterly Period, including amounts deducted by category from gross amounts invoiced to arrive at Net Sales; 

(b)    a reasonably detailed calculation of the COGs for Product invoiced during such Quarterly Period; 

(c)    calculation of Gross Profit; and 

(d)    the total amounts due to Pfenex under Section 4.5. 

Section 4.7    Payment Terms. All payments under this Agreement shall be made in Dollars and, unless otherwise
provided herein, shall be non-refundable and non-creditable. Any payments or portions thereof due hereunder which are not paid when due shall bear interest equal to the
lesser of the rate equal to the thirty (30) day effective federal fund rate (EFFR) for the date that payment was due, as published by The Wall Street Journal, Internet Edition at www.wsj.com in the “Money Rates” column,
plus an additional two hundred (200) basis points, or the maximum rate permitted by Applicable Law, calculated on the number of days such payment is delinquent. This Section 4.7 shall in no way limit any other remedies available to either
Party. 
 Section 4.8    Records; Audit Rights. Alvogen shall, and shall cause other Selling Persons to,
maintain complete and accurate books and records, in sufficient detail to confirm the accuracy of payments and costs with respect to payments under this Agreement (the “Product Financial Records”). Alvogen shall retain all Product
Financial Records for a period of at least three (3) years or for such longer period to the extent required by Applicable Law. During such period, upon the written request of Pfenex, the Product Financial Records shall be subject to inspection
and audit by and at the expense of Pfenex no more than two times in any Annual Period, unless for cause. Such audits shall occur upon reasonable notice and during normal business hours by an independent auditor selected by Pfenex and reasonably
acceptable to Alvogen. Pfenex shall treat all information received or subject to review under this Section 4.8 as Confidential Information of Alvogen in accordance with the provisions of Article VIII. Pfenex shall cause its independent auditor
to enter into a confidentiality agreement, in form and substance reasonably acceptable to Alvogen, to maintain such records and information of 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

20 

 
Alvogen in confidence in accordance with Article VIII and not use such records or information except to the extent permitted by this Agreement, including any enforcement of the provisions hereof.
If any such audit reveals that Alvogen has failed to accurately make any payment required under this Agreement, then Alvogen shall promptly pay to Pfenex any underpaid amounts due under this Agreement, together with interest calculated as set forth
in Section 4.7, or Pfenex shall promptly pay to Alvogen any overpaid amounts paid under this Agreement, as the case may be. If any such audit reveals an underpayment of amounts due under this Agreement greater than five percent (5%) of the
amounts actually due for any Annual Period, then Alvogen shall pay the reasonable out-of-pocket costs incurred in conducting such audit. 

Section 4.9    Costs. Except as otherwise expressly provided herein, each Party shall bear all costs and
expenses of carrying out those activities allocated to it hereunder, including the costs and expenses of its Affiliates and Third Parties acting on its and its Affiliates’ behalf or under their authority. 

Section 4.10    Annual Reconciliation and True-up. Certain payments
and measurement periods in this Agreement are based on Quarterly Periods, including but not limited to the Distribution Cost Allowance, Gross Profit, and Manufacturing Costs. The Parties shall perform a reconciliation of all such amounts at the end
of each Annual Period to determine what such amounts would have been if they had been measured on the basis of an Annual Period (with appropriate adjustments or consolidation of related caps, threshold amounts, and other calculations). If the amount
of any such payments that would have been made under this Agreement for such Annual Period would have been different than the payments calculated for the corresponding Quarterly Periods, then the Parties shall adjust the payments in the last
Quarterly Period to eliminate such difference. The Parties, through the Executive Steering Committee, shall establish a mechanism and timing to facilitate such reconciliation. 

ARTICLE V 
 MANUFACTURE
OF PRODUCT; SALES AND MARKETING 
 Section 5.1    Manufacturing Responsibility. 

(a)    Except for the Product necessary for Pfenex to conduct the activities described in Section 3.1, Alvogen shall
be responsible for and control the manufacturing of Product (and components thereof including Drug Substance and any assembly and packaging of finished Products), for qualification of the components required for the manufacture of such Product and
preparing, filing and obtaining all related and necessary Registrations (with the exception of the NDA, which is addressed in Section 3.1) necessary for such manufacture for all purposes under this Agreement, including for Commercialization, in
the Territory. In connection therewith, Alvogen may elect to manufacture, fill and package Product itself or engage one or more Third Parties to manufacture, fill or package Product on its behalf (each, a “Third Party Supplier”);
however, such engagement (other than with respect to Third Parties previously engaged by Pfenex for such purpose) shall be subject to the prior approval of Pfenex, not to be unreasonably withheld conditioned or delayed. For clarity, Pfenex shall be
responsible for the supply of all Product necessary for the conduct of the activities described in Section 3.1. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

21 

 (b)    Promptly after the Effective Date, Alvogen shall assume
responsibility for establishing commercial supply agreements with each of Pfenex’s existing Third Party suppliers of Product (and components thereof including Drug Substance) in the supply chain for Product, the identity of which suppliers have
been disclosed to Alvogen. At the request of Alvogen, Pfenex shall cooperate with and reasonably assist Alvogen to negotiate and enter into such agreements. 

Section 5.2    Manufacturing Cooperation. 

(a)    Promptly (but no later than thirty (30) days) after the Effective Date, the Parties shall mutually develop a
plan (together with a budget therefor) for the reduction of COGs for the Product (the “COGs Reduction Plan”), which plan shall be based upon the initial draft elements described in Exhibit 5.2. Thereafter, [***]. 

(b)    Without limiting Alvogen’s obligations under this Section 5.2 and at the request of Pfenex, the Parties
agree to discuss through the Executive Steering Committee the possibility of coordinating or otherwise using common sourcing, contract manufacturer(s) or otherwise for the manufacture and supply of Product (and components thereof including Drug
Substance) and any assembly and packaging of finished Products to (i) support the development and commercialization of the Product thereof (x) by or on behalf of Alvogen in the Territory (or outside the Territory to the extent that Alvogen
or its Affiliate is a commercial partner for a foreign equivalent of the Product in a country outside the Territory) and (y) by or on behalf of Pfenex (or its designee(s)) outside of the Territory, and (ii) take advantage of available
economies of scale and other synergies. If the Parties agree to any such coordination, then they will enter into a separate agreement referencing this Agreement setting forth the details of such agreement. 

Section 5.3    Product Packaging and Labeling. Subject to Section 6.1, Alvogen shall control the content
and type of packaging (and any changes or supplements thereto) for Product in the Territory. 

Section 5.4    Product Documentation. Subject to Section 6.1, Alvogen shall control the content and type
of, and procurement of, at its own expense, all Product Documentation (and any changes or supplements thereto) for Product in the Territory. 

Section 5.5    Product Recalls. Alvogen shall have the exclusive right to control, and shall be responsible
for, any recall of Product in the Territory. Any costs and expenses related to such recall shall be allocated in accordance with Article XI. 

Section 5.6    Product Pricing and Promotion; Agency Contacts. 

(a) Subject to Section 6.1, Alvogen shall, at its sole expense, have the exclusive right to control, and shall be responsible for, the
advertising, marketing, promotion (including preparing and distributing Product Documentation), sales prices and pricing, promotional and marketing strategies and terms of sale for Product in the Territory. Alvogen shall be the contact for review
and discussion of all Product Documentation for Product with the applicable Governmental Authorities in the Territory. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

22 

 (b)    If Alvogen or any of its Affiliates sells Product to a Third
Party to whom it also sells or otherwise provides other products or services (which are not Bundled Products), Alvogen and its Affiliates shall not shift, allocate, price, discount or otherwise weigh payments received in any such transaction or any
combination of transactions, with the purpose of reducing or disadvantaging the Net Sales of Product in favor of any other product, service or consideration in order to reduce the payments owed by Alvogen to Pfenex hereunder. 

Section 5.7    Sales and Marketing. After the Transfer Effective Date, Alvogen shall use Diligent Efforts
(including with respect to the timing of the launch of Product) to Commercialize Product in the Territory. 

Section 5.8    Ex-Territory Sales; Export Monitoring. 

(a)    Ex-Territory Sales. Subject to Applicable Law and any written
agreement covering Commercialization efforts outside the Territory, neither Party shall engage in any advertising or promotional activities relating to Product directed primarily to customers or other buyers or users of Product located outside the
Territory in the case of Alvogen or inside the Territory in the case of Pfenex (or other Persons acting under its or its Affiliates’ authority) (such territory with respect to such Party, the “Commercial Territory”) or accept
orders for Product from or sell Product into the other Party’s Commercial Territory for its own account, and if a Party receives any order for Product in the other Party’s Commercial Territory, it shall refer such orders to the other
Party. 
 (b)    Export Monitoring. Each Party shall use Diligent Efforts to monitor exports of Product from its
own Commercial Territory for commercialization in the other Party’s Commercial Territory using methods permitted under Applicable Law that are commonly used in the industry for such purpose, and shall promptly notify the other Party of any such
exports of Product from its Commercial Territory. Each Party agrees to take reasonable actions requested in writing by the other Party that are consistent with Applicable Law to prevent exports of Product from its Commercial Territory for
Commercialization in the other Party’s Commercial Territory. 
 ARTICLE VI 

PRODUCT TRADEMARK; INTELLECTUAL PROPERTY LITIGATION 

Section 6.1    Product Trademarks. 

(a)    Subject to the terms and conditions of this Agreement, Pfenex hereby grants to Alvogen an exclusive, transferable
(solely in accordance with and subject to Section 12.7), sublicensable (solely in accordance with and subject to Section 2.2) license to use the Product Trademark solely for Commercialization of Product in the Territory during the Term
(the “Trademark License”). To the extent that Alvogen obtains any right in the Product Trademark (including any goodwill associated therewith), Alvogen hereby assigns the same to Pfenex. 

(b)    Prior to receipt of notice from the FDA that the Product is Therapeutically Equivalent to the Reference Product,
Alvogen shall Commercialize Product in the Territory 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

23 

 
solely under the Product Trademark, provided that Alvogen shall otherwise have the sole right to select the trade dress, style of packaging, labeling and the like used in connection with the
Commercialization of Product in the Territory, including promotional or advertising taglines. The Commercialization of Product in the Territory under any Trademark other than the then-existing Product Trademark (or any Trademark specific to Alvogen
or its Affiliate) shall be subject to the prior written consent of Pfenex, not to be unreasonably withheld, delayed or conditioned. If Pfenex so consents, any such other trademark under which Product is Commercialized in the Territory, including all
goodwill associated therewith, shall collectively be within the Product Trademark and Pfenex shall be the exclusive owner of each Product Trademark and licensed to Alvogen pursuant to Section 6.1(a). Pfenex shall register and renew, at its
expense, each such Product Trademark in the Territory. 
 (c)    Alvogen shall fully comply with all reasonable
guidelines, if any, communicated in writing by Pfenex concerning the use of the Product Trademark. Alvogen shall not challenge or assist others to challenge the Product Trademark (except to the extent such restriction is expressly prohibited by
Applicable Law) or the registration thereof or attempt to register any trademarks, marks or trade names confusingly similar to those of Pfenex. Alvogen shall not engage in any activity that would adversely affect the name, reputation or goodwill of
Pfenex or the Product. Except as set forth in this Section 6.1, nothing contained in this Agreement shall grant or shall be deemed to grant to Alvogen any right, title or interest in or to the Product Trademark. Upon termination of this
Agreement, Alvogen shall immediately cease to use the Product Trademark. 
 (d)    To the extent permitted by Applicable
Law, at Pfenex’s election, the Product Documentation, including labels (subject to space limitations) shall include the Pfenex tradename and associated mark (as may be updated from time to time, the “Pfenex Housemark”) to be
placed in a size (but at least seventy-five percent (75%) of that of Alvogen or its Affiliate) and location reasonably agreed to by the Parties and consistent with the standards of the pharmaceutical industry. Subject to the foregoing, Pfenex hereby
grants to Alvogen, its Affiliates and Third Party distributors a limited right to use the Pfenex Housemark solely in connection with the sale and marketing of Product in the Territory in accordance with this Agreement. The Pfenex Housemark and all
goodwill associated therewith, and all applications, registrations, extensions and renewals and other rights relating thereto, shall be the sole property of Pfenex. Accordingly, to the extent Alvogen obtains any right with respect thereto, it hereby
assigns the same to Pfenex. Pfenex shall have the sole right to register and renew, at its expense, the Pfenex Housemark, or any portion thereof, in any country or jurisdiction of Pfenex’s choosing. 

Section 6.2    Ownership of Product Inventions. All right, title and interest in and to all inventions and Know-How, including all Intellectual Property rights in the foregoing, made, conceived, reduced to practice or otherwise generated by or on behalf of a Party or its Affiliates, or jointly by or on behalf of the
Parties or their Affiliates, in connection with this Agreement including Alvogen’s manufacture and supply of Product (collectively, “Product Inventions”) shall be solely owned by Pfenex. Alvogen hereby assigns to Pfenex all of
its right, title and interest in and to all Product Inventions (including related Patents and Know-How) and agrees to execute and deliver all documents and instruments reasonably requested by Pfenex to effect,

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

24 

 
evidence or record the foregoing assignment. Alvogen shall promptly disclose to Pfenex all Product Inventions made, conceived, reduced to practice or otherwise generated by or on behalf of
Alvogen or its Affiliates, solely or jointly, and shall promptly respond to reasonable requests from Pfenex for additional information relating to such Product Inventions. 

Section 6.3    Patent Prosecution and Maintenance of Product Inventions. 

(a)    Pfenex shall have the first right to Prosecute and Maintain all Patents claiming Product Inventions, at its own cost
and expense, in the Territory. Pfenex shall consult with Alvogen and keep Alvogen reasonably informed of the status of such Patents in the Territory and shall promptly provide Alvogen with all material correspondence received from the U.S. Patent
and Trademark Office (the “PTO”) in connection therewith. In addition, Pfenex shall promptly provide Alvogen with drafts of all proposed material filings and correspondence to the PTO with respect to such Patents for Alvogen’s
review and comment prior to the submission of such proposed filings and correspondence. Pfenex shall consider in good faith any comments provided by Alvogen in a timely manner, prior to submitting such filings and correspondence to the PTO. If
Pfenex decides to discontinue the Prosecution or Maintenance of any such Patent, it shall notify Alvogen of such decision. Thereafter, Alvogen shall have the right, but not the obligation, to Prosecute and Maintain such Patent at its own cost and
expense, if doing so does not, in Pfenex’s reasonable, good faith determination, cause a material adverse effect on Pfenex’s Intellectual Property rights covering products other than Product. 

(b)    Alvogen acknowledges the highly proprietary and confidential nature of unpublished patent applications and related
information and without limiting the provisions of Article VIII agrees to limit the access to any such applications and information received from Pfenex hereunder to those who need such access for the purposes of this Section 6.3 and limit the
use thereof solely to the purposes of this Section 6.3. Without limiting the foregoing, any disclosures made pursuant to this Section 6.3 will be structured in a manner so as to provide reasonable access to the applicable information while
limiting the risk of adversely affecting the patentability of the subject matter disclosed. 

Section 6.4    Third Party Actions. 

(a)    In the event that any Third Party commences any Action against either Party or any of such Party’s Affiliates
alleging that the Product (including the use or the manufacture of Product) infringes any Intellectual Property of such Third Party in the Territory (a “Third Party Action”), the Party against whom such Action is commenced shall
provide the other Party prompt written notice thereof, and Alvogen shall have the sole right and responsibility to control the defense of such Third Party Action (including the right to seek any license from such Third Party, or enter into any
settlement or compromise or consent to any judgment with respect thereto) at Alvogen’s sole expense. If Pfenex or its Affiliate is a defendant, then Pfenex or its Affiliate shall have the right to participate with counsel of its selection (at
its cost and expense) and Alvogen shall use counsel reasonably acceptable to Pfenex, at Alvogen’s sole cost and expense, and Alvogen shall continue to control and defend Pfenex or its Affiliate until final judgment or settlement in such Third
Party Action. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

25 

 (b)    Pfenex shall provide cooperation and assistance reasonably
requested by Alvogen in connection with any such Third Party Action, including (i) providing Alvogen with detailed responses to its inquiries, and (ii) identifying and providing witnesses who will assist in the preparation of evidence,
provide written evidence, appear as witnesses in court. 
 (c)    In the event that, in the reasonable judgment of
Alvogen (after consultation with Pfenex), a Third Party is likely to commence an Action against either Party or any of such Party’s Affiliates alleging that the Product (including the use or the manufacture of Product) infringes any
Intellectual Property of such Third Party in the Territory, then Alvogen shall have the sole right and responsibility to conduct inter partes actions, conduct post-grant proceedings before the PTO or seek a declaratory judgment in respect of any
Patent that may be asserted against the Product. 
 Section 6.5    Enforcement Actions. 

(a)    Each Party shall promptly give the other Party written notice (each, an “Infringement Notice”) of
any actual or suspected infringement, misappropriation or other violation by a Third Party of the Pfenex Technology in the Territory (“Infringing Activity”) that come to such Party’s or any of its Affiliates’ attention, as
well as the identity of such Third Party and any evidence of such Infringing Activity within such Party’s or any of its Affiliates’ custody or control that such Party or any of its Affiliates is reasonably able to provide. 

(b)    Alvogen shall have the first right, but not the obligation, at its sole cost and expense, to take any action in
response to Infringing Activity arising from the development, manufacture and/or Commercialization of a Competing Product in the Territory (each, an “Enforcement Action”) and to enter into or permit the settlement of such
Enforcement Action; provided that Alvogen shall provide prompt written notice of any Enforcement Action to Pfenex, permit Pfenex (subject to the Common Interest Agreement) to review and comment on such Enforcement Action and give reasonable
consideration to any comments made by Pfenex in relation to such Enforcement Action. If required by Applicable Law and to the extent Alvogen does not have standing, Pfenex shall permit, and shall take all actions reasonably necessary to enable, an
Enforcement Action to be brought in its name, including being joined as a necessary party, at Alvogen’s sole cost and expense (other than any counsel selected separately to represent Pfenex). Alvogen may not settle, compromise or consent to any
judgment with respect to any Enforcement Action without the prior written consent of Pfenex, not to be unreasonably withheld, conditioned or delayed. Notwithstanding the foregoing, Alvogen shall not have the right to initiate an Enforcement Action
if Pfenex has provided notice to Alvogen specifying that, in Pfenex’s reasonable opinion (based on advice of patent counsel), (i) the initiation of such Enforcement Action is likely to invalidate or narrow the claims of any Pfenex Patent
and (ii) such invalidation or narrowing would likely have a material adverse impact on Pfenex or its Affiliates or the Pfenex Technology. 

(c)    If Alvogen does not institute an Enforcement Action against the Infringing Activity within three (3) months
from the date of the Infringement Notice, Pfenex shall have the right, but not the obligation, at Pfenex’s sole cost and expense, to bring the Enforcement Action; provided that Pfenex shall provide prompt written notice of any such Enforcement
Action to 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

26 

 
Alvogen, permit Alvogen (subject to the Common Interest Agreement) to review and comment on strategic decisions and material pleadings and communications regarding such Enforcement Action and
give reasonable consideration to any comments made by Alvogen in relation to such Enforcement Action. In such case and if required by Applicable Law and to the extent Pfenex does not have standing, Alvogen shall permit, and shall take all actions
reasonably necessary to enable, an Enforcement Action to be brought in its name, including being joined as a necessary party, at Alvogen’s sole cost and expense. Pfenex may not enter into any settlement or consent to any judgment with respect
to any such Enforcement Action without the prior written consent of Alvogen, not to be unreasonably withheld, delayed or conditioned. 

(d)    In any Enforcement Action instituted by either Pfenex or Alvogen to enforce the Pfenex Technology as provided
herein above, the other Party (the “Cooperating Party”) shall, at the reasonable request of the Party initiating such Enforcement Action (the “Enforcing Party”), cooperate and provide reasonable assistance to the
Enforcing Party, including (i) providing the Enforcing Party with documents (whether in written, electronic or other form) related to the Pfenex Technology in the Territory, (ii) identifying and describing any Intellectual Property that
has been incorporated into the Pfenex Technology in the Territory by the Cooperating Party, (iii) allowing inspection, whether court-ordered or otherwise, of any facility owned, operated or controlled by the Cooperating Party in the Territory,
and (iv) identifying and providing witnesses who will assist in the preparation of evidence, provide written evidence, appear as witnesses in court and assist in other ways that the Enforcing Party reasonably requests. To the extent that the
cooperation or assistance requested results in external costs being incurred by the Cooperating Party, then the Enforcing Party shall be responsible for the payment of all reasonably incurred external expenses. 

Section 6.6    Patent Extensions; Orange Book Listings; Patent Certifications. If elections with
respect to obtaining patent term extension or supplemental protection certificates or their equivalents in Territory with respect to the Product becomes available, upon NDA Approval for the Product, Pfenex and Alvogen shall mutually agree on the
determination of which issued Patent to extend for the Product, and Alvogen shall take such reasonable actions as are necessary to effectuate or assist in such extension. 

(a)    With respect to regulatory exclusivity periods, Pfenex, prior to the transfer of the NDA Approval, and Alvogen or
its Affiliate, following such transfer, shall be responsible for seeking and maintaining all such regulatory exclusivity periods that may be available for the Product in the Territory, subject to approval of the Party that is not responsible for
seeking and maintaining such exclusivity, such approval not to be unreasonably withheld, delayed or conditioned. The Party that is responsible therefor shall make all filings necessary to list the appropriate exclusivity periods and Pfenex
Patents, if any, in the Orange Book with respect to the Product, and the Parties shall mutually agree on which Pfenex Patents, if any, to list in the Orange Book with respect to the Product. 

(b)    Pfenex and Alvogen shall each notify and provide the other Party with copies of any notice of a Paragraph IV Patent
Certification (including any associated documents) by a Third Party filing an ANDA or an NDA, or any other similar patent certification by a Third Party in the Territory, in each such case referencing Product. Such notification and copies will

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

27 

 
be provided to the other Party promptly (but no later than within five (5) Business Days) after receipt of such notification and will be sent to the address set forth in Section 12.2.

 Section 6.7    Reimbursement Requirements.    To the extent that any Party would be
required pursuant to this Article VI to reimburse or pay the other Party for any costs or expenses incurred by such other Party, such obligation shall be subject to submission by such other Party of reasonable documentation with respect thereto. To
the extent that either Party would be entitled to be reimbursed for, or otherwise have paid, any costs or expenses incurred by such Party, such costs and expenses shall only be reimbursed or paid to the extent reasonably incurred by such Party and
submitted for reimbursement or payment pursuant to an invoice, which shall be payable in accordance with Section 4.7. 

Section 6.8    Recovered Amounts. [***]. 

Section 6.9    Common Interest Agreement. The Parties acknowledge they have entered into the certain common
interest agreement effective September 1, 2017 (the “Common Interest Agreement”). 

Section 6.10    Patent Marking. Alvogen shall mark (or cause to be marked) Product Commercialized in the
Territory with appropriate Pfenex Patent numbers or indicia as provided 35 U.S.C 287(a). 
 ARTICLE VII 

EXECUTIVE STEERING COMMITTEE 

Section 7.1    Formation and Purpose. In order to oversee, review and coordinate the activities of the Parties
under this Agreement, Pfenex and Alvogen will form an executive steering committee upon the Effective Date (the “Executive Steering Committee”), whose initial members are listed in the Product Memo. The Executive Steering Committee
shall, in accordance with the procedures set forth in Section 7.4, (a) review and comment on the development and Commercialization of Product in the Territory, (b) consult with Pfenex regarding filing the NDA with the FDA,
(c) review and comment on the creation and implementation of strategies related to the Pfenex Patents and Patents of Third Parties, in each case with respect to the development (including obtaining NDA Approval), Commercialization of Product in
the Territory (collectively, “IP Strategy”), (d) serve as a forum for discussion of matters relating to the development and Commercialization of Product in the Territory, (e) establish one or more working committees and
subcommittees as may be established by mutual consent of Pfenex and Alvogen (each, a “Working Committee”), and (f) perform such other duties as are specifically assigned to the Executive Steering Committee in this Agreement.
The Executive Steering Committee shall be the primary forum for Pfenex and Alvogen to communicate with one another regarding the plans for, and progress of, the development and Commercialization of Product in the Territory. 

Section 7.2    Membership. The Executive Steering Committee shall consist of three (3) employees of
Alvogen (or its Affiliate) appointed by Alvogen and three (3) employees of Pfenex appointed by Pfenex. Unless otherwise agreed by the Parties, the Executive Steering Committee and each Working Committee shall have at least one (1) member
with relevant decision-making 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

28 

 
authority from each Party such that such committee is able to effectuate all of its decisions within the scope of its responsibilities. Each Party shall ensure that each of its members of the
Executive Steering Committee shall be subject to the obligations of non-use and non-disclosure of Confidential Information set forth in Article VIII. 

Section 7.3    Meeting Requirements. The Executive Steering Committee shall meet on a quarterly basis (or more
or less frequently if Pfenex and Alvogen mutually agree) during the Term, and shall hold its first meeting within thirty (30) days after the Effective Date. The Executive Steering Committee may meet by phone, videoconference or in person. Each
meeting shall be held on a date to be agreed upon by Pfenex and Alvogen. Notwithstanding the foregoing, meetings may be called at any time if requested by either Party by prior written notice, including the proposed agenda of the meeting, sent to
the other Party at least two (2) weeks in advance; provided that if a meeting is requested to be convened urgently pursuant to this Agreement, Pfenex and Alvogen shall convene such meeting as promptly as is practicable. At least one
(1) member designated by Alvogen and one (1) member designated by Pfenex shall be required to be present at or participating in the meeting in order to establish a quorum for such meeting. Each Party shall be able to invite a reasonable
number of observers (who may include consultants and experts) to each Executive Steering Committee; provided that each such individual is subject to confidentiality obligations consistent with the provisions of Sections 8.1, 8.2 and 8.3. 

Section 7.4    Decision-Making; Dispute Resolution. 

(a)    The Executive Steering Committee shall have a single chairperson who shall (i) solicit agenda items from the
other Executive Steering Committee members, coordinate and prepare the agenda (which shall include any agenda items reasonably proposed by Executive Steering Committee members from the other Party), provide the agenda along with appropriate
information for such agenda reasonably in advance (to the extent possible) of any meeting and ensure the orderly conduct of the Executive Steering Committee’s meetings, (ii) attend (subject to the below) each meeting of the Executive
Steering Committee, and (iii) prepare and issue minutes of each meeting (which shall accurately reflect the discussions and decisions of the Executive Steering Committee at such meeting) in accordance with Section 7.5. Such minutes from
each Executive Steering Committee meeting shall not be finalized until the Executive Steering Committee members from the other Party have reviewed and confirmed the accuracy of such minutes as described in Section 7.5 and if not previously
confirmed, such matter shall be the first order of business at the next Executive Steering Committee meeting. The Party appointing the chairperson shall alternate between Pfenex and Alvogen every calendar year, and shall initially be designated by
Alvogen. In the event the chairperson or another member of the Executive Steering Committee from either Party is unable to attend or participate in any meeting of the Executive Steering Committee, the Party who appointed such Executive Steering
Committee chairperson or member may appoint a substitute chairperson or other member for that meeting. All decisions of the Executive Steering Committee and any Working Committee shall be made by consensus, with each Party having one (1) vote.
Each Party shall work in good faith to reach consensus on matters and in no event shall either Party unreasonably withhold, condition or delay any approval or other decision of the Executive Steering Committee or a Working Committee hereunder. In
the event a Working Committee fails to reach consensus with 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

29 

 
respect to a particular matter within its authority, then upon request by either Party such matter shall be referred to the Executive Steering Committee for resolution. 

(b)    If the Executive Steering Committee is unable to reach a decision as to any matter within its authority (including
any matter expressly required to be resolved by the Executive Steering Committee pursuant to this Agreement) after a period of ten (10) Business Days, then either Pfenex or Alvogen may provide written notice of such dispute to the President or
Chief Executive Officer of the other Party and such matter shall be resolved as set forth below. The Chief Executive Officers (or their respective designees, who shall be senior officer of Pfenex and Alvogen, but shall not be members of the
Executive Steering Committee) of each of Pfenex and Alvogen shall discuss the dispute in person or telephonically and use their good faith efforts to resolve the dispute within thirty (30) days after submission of such dispute to such officers.
If any such dispute is not resolved by the Chief Executive Officers or their designees within thirty (30) days after submission of such dispute to such officers, then: 

(i)    the Chief Executive Officer of Pfenex shall have authority to finally resolve, in such officer’s reasonable
discretion exercised in good faith, all disputed matters related to (A) the Pfenex Technology and the Prosecution and Maintenance of Patents claiming Product Inventions and the enforcement thereof (except for matters that Alvogen has the right
to control pursuant to Section 6.5(c)), (B) communications with the FDA and the content of the NDA and other Regulatory Materials (up and through the date of the Transfer Notice), (C) the Development Plan prior to the Transfer Notice
and the conduct of the activities thereunder as described in Section 3.1(a), (D) the content of proposed publications or presentations under Section 8.8, (E) the COGs Reduction Plan or the implementation thereof under Section 5.2(a)
and (F) the existence of Safety Reasons under either Section 10.2(a)(iii) or Section 10.2(b)(iii); and 

(ii)    the Chief Executive Officer of Alvogen shall have authority to finally resolve, in such officer’s reasonable
discretion exercised in good faith, all matters related to (A) IP Strategy (other than as referenced in Section 7.4(b)(i)(A)), (B) regulatory affairs with respect to Product in the Territory (including communications and filings with
the FDA) (only after the Transfer Notice as referenced in Section 7.4(b)(i)(B)) and (C) the manufacture and Commercialization of Product in the Territory. 

Section 7.5    Meeting Minutes. The Parties shall reasonably cooperate to finalize the definitive minutes of
the Executive Steering Committee no later than thirty (30) days after the meeting to which the minutes pertain, as follows: (a) the chairperson of the Executive Steering Committee shall be responsible for preparing and sending a draft of
the minutes to the other Party’s members, and shall furnish such draft within ten (10) days of such meeting, (b) the other Party’s members shall have ten (10) days after receiving the draft minutes to collect comments and to
discuss any modifications thereof, and (c) within the following ten (10) days any disputes as to the minutes shall be resolved between the Parties and the final version of the minutes shall be issued by the Party appointing the chairperson
which shall be subject to approval by Alvogen and Pfenex by signing and dating the minutes or unanimous approval of the Executive Steering Committee at its next meeting. The minutes shall include a list of any actions, decisions or determinations
approved by the Executive Steering Committee and a list of any issues yet to be 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

30 

 
resolved. In addition, the minutes shall set forth the place and date where the next meeting shall be held. 

Section 7.6    Expenses. Each of Pfenex and Alvogen shall be responsible for the expenses of the participation
of its members in the Executive Steering Committee and any Working Committees, including travel costs. 

Section 7.7    Working Committees. Each Working Committee shall (a) be comprised as the Executive
Steering Committee determines is necessary to fulfill its responsibilities (it being understood that a particular Working Committee may not necessarily have the same number of members from each Party), and (b) report into and be subordinate to
the Executive Steering Committee. A Working Committee shall only have the authority expressly delegated to such Working Committee by the Executive Steering Committee. Each Working Committee shall keep the Executive Steering Committee regularly
informed of the activities that it is tasked with overseeing or otherwise carrying out, both through in-person and written reporting as reasonably necessary for the Executive Steering Committee to fulfill its
responsibilities with respect thereto. 
 Section 7.8    Committee Authority. Notwithstanding the creation
of the Executive Steering Committee and any Working Committee, each Party shall retain the rights, powers and discretion granted to it under this Agreement, and no committee shall be delegated or vested with rights, powers or discretion unless such
delegation or vesting is expressly provided herein, or the Parties expressly so agree. Neither the Executive Steering Committee nor any Working Committee shall have the power to (a) amend, modify or waive compliance with this Agreement,
(b) to determine whether or not a Party has met its diligence or other obligations under the Agreement, or (c) to determine whether or not a breach of this Agreement has occurred, and no decision of the Executive Steering Committee or any
such Working Committee, as applicable, shall be in contravention of any terms and conditions of this Agreement. It is understood and agreed that issues to be formally decided by the Executive Steering Committee and any Working Committee, as
applicable, are only those specific issues that are expressly provided in this Agreement to be decided by the Executive Steering Committee and any such Working Committee, as applicable. 

Section 7.9    Day-to-Day
Responsibilities. Each Party shall be responsible for day-to-day implementation and operation of the activities under this Agreement for which it has or is otherwise
assigned responsibility under this Agreement, provided that such implementation is not inconsistent with the express terms and conditions of this Agreement, the decisions of the Executive Steering Committee or any Working Committee within the scope
of its authority specified herein or Applicable Law. In the event that Pfenex renders such a binding decision, Pfenex shall provide Alvogen with written notice of the decision within thirty (30) days, including a description, in reasonable
detail, of Pfenex’s reasoning in support of the decision. 
 Section 7.10    Cooperation; Withdrawal.

 (a)    A Party that is obligated to cooperate with the other Party hereunder (i) may consider all relevant
factors including its other then-current obligations and resource commitments when determining whether the cooperation activities are reasonable, and (ii) shall not be obligated to obtain any additional resources (including hire any personnel)
to accomplish 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

31 

 
its cooperation hereunder. Such Party’s obligation to cooperate in a particular activity shall not alleviate the other Party’s obligation to perform the underlying activity. 

(b)    At any time after proper delivery of the Transfer Notice, and for any reason, Pfenex shall have the right to
withdraw from participation in the Executive Steering Committee or any or all of the Working Committees upon notice to Alvogen referencing this Section 7.10(b), which notice shall be effective immediately upon receipt. Thereafter, (i) any
information, documents or reports that a Party is otherwise required to provide to the Executive Steering Committee pursuant to this Agreement shall be provided directly to the other Party, and (ii) any matters delegated to the Executive
Steering Committee pursuant to this Agreement shall be made by mutual written agreement of the Parties, subject to the dispute resolution and final decision-making provisions of Section 7.4(b). For purposes of clarification, Pfenex’s
withdrawal from the Executive Steering Committee or any Working Committee shall not affect any other obligation or responsibility of Pfenex set forth in this Agreement. 

ARTICLE VIII 

CONFIDENTIALITY; TAXES; NONSOLICITATION; PUBLICATIONS 

Section 8.1    Confidentiality. Each of Pfenex and Alvogen acknowledges that, in the course of discussions and
negotiations and performing its obligations hereunder, (a) it has received or may receive information from the other Party and (b) the other Party may disclose to it information, data and processes that such other Party wishes to protect
from use by and disclosure to Third Parties (all information described in clauses (a) and (b), unless subject to the Confidentiality Exceptions, “Confidential Information”). Each Party shall retain in confidence all
Confidential Information of the other Party and (except as expressly provided herein) shall not (i) use Confidential Information of such other Party for any purpose other than the purposes indicated herein and in connection with the performance
of this Agreement or (ii) disclose such Confidential Information to a Third Party other than its Agents without the written consent of such other Party. Confidential Information shall not include information that: (A) is or becomes public
knowledge (through no fault of the receiving Party or its Agents); (B) is made lawfully available to the receiving Party, other than under an obligation of confidentiality, by a Third Party that, to the knowledge of the receiving Party, is
under no duty of confidentiality to the disclosing Party; (C) is already in the receiving Party’s possession at the time of receipt from the disclosing Party (and such prior possession can be reasonably demonstrated by competent evidence
by the receiving Party) other than as a result of disclosure by a Third Party that, to the actual knowledge of the receiving Party, was under a duty of confidentiality to the disclosing Party with respect to such information; or (D) is
independently developed by the receiving Party or its Affiliates without the use of or reference to Confidential Information of the other Party (and such independent development can be reasonably demonstrated by competent evidence prepared by the
receiving Party) ((A) – (D), collectively, the “Confidentiality Exceptions”). Notwithstanding the foregoing, a receiving Party may use and disclose Confidential Information of the other Party (I) to the extent required by
Applicable Law; provided, however, that if legally permissible, the receiving Party shall give the disclosing Party advance written notice as promptly as is practicable to permit it to seek a protective order or other similar order, at the
disclosing Party’s sole cost, with respect to the disclosure of such Confidential Information, and, thereafter, the receiving Party shall disclose only the minimum Confidential Information that it is

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

32 

 
advised by counsel is required to be disclosed in order to comply, (II) to the extent such disclosure is reasonably necessary for the Prosecution and Maintenance of Patents (including
applications therefor) in accordance with Section 6.3, prosecuting or defending litigation, conducting preclinical or clinical studies, or obtaining and maintaining NDA Approval (including NDA Approval), (III) in communication with consultants
and advisors (including financial advisors, lawyers and accountants) and others on a need to know basis, in each case, under appropriate nondisclosure and non-use obligations substantially equivalent to those
of this Agreement (provided that the disclosing Party shall be responsible for any breach of this Section 8.1 by those parties to which it discloses Confidential Information), or (IV) to the extent mutually agreed to by the Parties in
writing. 
 Section 8.2    Agents. Each of Pfenex and Alvogen shall limit disclosure of the other
Party’s Confidential Information to only those of its Affiliates, directors, managers, officers, employees and others (collectively “Agents”) who are concerned with the performance of this Agreement, have a legitimate need to
know such Confidential Information in the performance of their duties and are bound by written obligations of non-disclosure and nonuse at least as protective of the disclosing Party and its Confidential
Information as the terms hereof. Each Party shall be responsible for any breach of Section 8.1 by its Agents and advisors (including financial advisors, lawyers and accountants) and shall take all reasonably necessary measures to restrain its
Agents and advisors (including financial advisors, lawyers and accountants) from unauthorized disclosure or use of the Confidential Information. 

Section 8.3    Restrictions on Sharing Information. Notwithstanding anything to the contrary, neither Party
shall be obligated pursuant to this Agreement to provide, or grant access to, any information (a) that it reasonably and in good faith considers to be Confidential Information it is prevented from disclosing to the other Party by an enforceable
confidentiality agreement with a Third Party and that such Party used Diligent Efforts to obtain the consent of such Third Party to provide or grant access to the other Party, (b) the disclosure of which would adversely affect the
attorney-client privilege between such Party and its counsel, or (c) the disclosure of which is not permitted pursuant to any Applicable Law or requirement of a Governmental Authority; provided in each case where information was not provided or
access was not granted as would otherwise be required under this Agreement, such Party shall inform the other Party of the reason it was not provided or granted and a description of the specific nature of the applicable information. Following the
Effective Date and during the Term, in connection with entering into any material agreement (or material amendment thereof) with any Third Party related to the Business, each Party agrees to use Diligent Efforts to negotiate with such Third Party to
include provisions in such agreement (or such amendment) sufficient to allow the other Party to receive relevant Confidential Information of such Third Party. 

Section 8.4    Prior Agreements. This Agreement supersedes the Prior Agreements in their entirety, including
with respect to information disclosed thereunder. All information exchanged between the Parties under the Prior Agreements shall be deemed Confidential Information of the disclosing Party and shall be subject to the terms of Section 8.1,
Section 8.2 and Section 8.3. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

33 

 Section 8.5    Taxes. 

(a)    The Parties agree that for U.S. federal income tax purposes they will treat the transaction under this Agreement,
unless otherwise required by Applicable Law, as a collaboration agreement that does not constitute a partnership or a joint venture, and agree to not take (or cause any Person to take), any position on any Tax return or in the course of any audit,
examination or other proceeding inconsistent with such treatment, unless otherwise required by Applicable Law and except upon a final determination of the applicable Taxing Authority. 

(b)    Any and all payments by or on account of any obligation of any Party under this Agreement shall be made without
deduction or withholding for any Taxes, except as required by Applicable Law. If any Applicable Law (as determined in the reasonable and good faith discretion of the applicable withholding Party) requires the deduction or withholding of any Tax from
any such payment by any Party, then the applicable Party shall be entitled to make such deduction or withholding, any amount so deducted or withheld shall be deemed paid to the other Party that was entitled to the payment subject to withholding,
shall timely pay the full amount deducted or withheld to the relevant Taxing Authority in accordance with Applicable Law. To Alvogen’s Knowledge, Applicable Law, does not require Alvogen to withhold any of Taxes from any payment required under
this Agreement. To the extent that as a result of any change in any Tax law a payment to Pfenex pursuant to this Agreement becomes subject to U.S. federal or Malta withholding Tax (or to an increased rate of such withholding) after the date hereof,
Alvogen shall indemnify Pfenex, within ten (10) days after demand therefor, for the full amount of any withholding Taxes imposed on such payment (including U.S. federal or Malta withholding Tax imposed on amounts payable under this
Section 8.5(b)). Notwithstanding anything to the contrary, if Pfenex or any Affiliate thereof actually obtains a refund or a credit from any Taxing Authority for any portion of any Tax for which it was indemnified under this Section 8.5(b)
by Alvogen, Pfenex shall promptly reimburse Alvogen the amount of such refund or credit; and, upon request by Alvogen, Pfenex shall obtain available refunds or credits with respect to any such Taxes. 

(c)    Any Assignee shall indemnify the Non-Assigning Party, within ten
(10) days after demand therefor, for the full amount of any Indemnified Taxes (including Indemnified Taxes imposed or asserted on or attributable to amounts payable under this Section 8.5) payable or paid by such Non-Assigning Party or required to be withheld or deducted from a payment to such Non-Assigning Party and any reasonable expenses arising therefrom or with respect thereto,
whether or not such Indemnified Taxes were correctly or legally imposed or asserted by the relevant Taxing Authority. Notwithstanding anything to the contrary in this Agreement, if a Party (the “Taxed Party”) obtains a refund or
credit from any Taxing Authority for any portion of any Indemnified Tax paid by the other Party, then the Taxed Party shall promptly reimburse the other Party the amount of such refund or credit (but only to the extent of payments made under this
Section 8.5(c) with respect to the Taxes giving rise to such refund or credit), net of all out-of-pocket expenses (including Taxes) of such Taxed Party and without
interest (other than interest paid by the relevant Taxing Authority with respect to such refund or credit), and upon request, the Taxed Party shall use Diligent Efforts to obtain available refunds or credits with respect to any such Indemnified
Taxes provided, however, that such Taxed Party, upon the request of such Taxed Party, shall repay to such Taxed Party the amount of refund or credit paid 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

34 

 
over pursuant to this sentence in the event that such Taxed Party is required to repay such refund or credit to such Taxing Authority. 

(d)    All transfer, documentary, sales, use, excise, customs, charges, duties, ad valorem, value added, stamp,
registration, recording, property and other such similar Taxes (other than, for the avoidance of doubt, Taxes assessed against income), and all conveyance fees, recording charges and other fees and charges (including any penalties and interest)
lawfully assessed or charged in connection with any of the transactions contemplated under this Agreement (collectively, “Transfer Taxes”) shall be paid and borne 50% by Alvogen and 50% by Pfenex when due, and the Party responsible
under such Applicable Law for paying such Transfer Taxes shall, at its own expense, file all necessary Tax returns and other documentation with respect to all such Transfer Taxes and pay such Taxes, and, if required by Applicable Law, the Parties
will, and will cause their Affiliates to, join in the execution of any such Tax returns and other documentation. 

(e)    The Parties agree to cooperate with one another and use reasonable efforts to reduce or eliminate tax withholding
or similar obligations in respect of royalties, milestone payments, and other payments made by Alvogen to Pfenex under this Agreement. Pfenex shall provide Alvogen any tax forms that may be reasonably necessary in order for Alvogen not to withhold
tax or to withhold tax at a reduced rate under an applicable bilateral income tax treaty. Each Party shall provide the other with reasonable assistance to enable the recovery, as permitted by applicable Laws, of withholding taxes, value added taxes,
or similar obligations resulting from payments made under this Agreement, such recovery to be for the benefit of the Party bearing such withholding tax or value added tax. 

Section 8.6    Nonsolicitation. Each Party (for purposes of this Section 8.6, a “Soliciting
Party”) agrees that, during the Term, such Soliciting Party will not solicit for employment or consultancy, employ or engage as a consultant or solicit the termination of employment or consultancy with the other Party (a
“Solicitation Action”), any individual that at the time of such Solicitation Action (a) is an officer or employee of the other Party or a consultant that is devoting a majority of such individual’s time to the business of
the other Party, and (b) is or was actively involved in the other Party’s performance of its obligations hereunder; provided, however, that the foregoing shall not prohibit (i) any advertisement or general solicitation (or hiring or
engagement as an employee or consultant as a result thereof) for employment or consultancy not specifically directed at any such individual, (ii) the hiring or engagement as an employee or consultant of any such individual who initiates
employment or consultancy discussions with such Soliciting Party, provided that such initial discussions are not encouraged or solicited by such Soliciting Party, or (iii) any Solicitation Action with respect to any individual following the
cessation of such individual’s employment with (or service as a consultant that is devoting a majority of such person’s time to the business of) the other Party without any solicitation or encouragement by such Soliciting Party. 

Section 8.7    Public Announcements. Neither Party nor their respective Affiliates shall make any public
announcement regarding this Agreement or disclose the terms and conditions of this Agreement to any Third Party without the prior written consent of the other Party (not to be unreasonably withheld, delayed or conditioned), except (a) to
advisors (including consultants, 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

35 

 
financial advisors, attorneys and accountants) on a need to know basis, in each case, under circumstances that reasonably protect the confidentiality thereof, (b) to actual and potential
(i) licensees and collaborators with respect to Product, and (ii) investors and acquirers of the Business or otherwise a majority of the business or assets of such Party related to this Agreement in connection with negotiations of
definitive agreements, under reasonable conditions of confidentiality, or (c) to the extent such disclosure is required by Applicable Law (including securities laws). Notwithstanding the foregoing, (A) without the prior written consent of
the other Party, either Party may (I) file with the Securities and Exchange Commission (the “SEC”) a Current Report on Form 8-K describing this Agreement and the transactions contemplated
hereby and (II) file a copy of this Agreement with the SEC as an exhibit to such Current Report on Form 8-K or a subsequent periodic report; provided that the filing Party shall consult with the other
Party so as to minimize the necessary disclosure and shall seek confidential treatment of such portions of this Agreement or the terms and conditions thereof as permitted under Applicable Laws, and (B) the Parties agree to issue a joint press
release announcing the execution of this Agreement, which is attached hereto as Exhibit 8.7. Thereafter, Pfenex and Alvogen may each disclose to Third Parties the information contained in such Current Report on Form 8-K or such press release without the need for further approval by the other Party. 

Section 8.8    Publications. Alvogen may publish or present data or results relating to Product in scientific
journals with primary circulation in the Territory or at scientific conferences in the Territory, subject to the prior review, comment and approval by Pfenex as set forth in this Section 8.8, which approval shall not be unreasonably withheld,
delayed or conditioned. Alvogen shall provide Pfenex with the opportunity to review any proposed abstract, manuscript or presentation which discloses information relating to Product by delivering a copy thereof to Pfenex no less than thirty
(30) days before its intended submission for publication or presentation. Pfenex shall have ten (10) days from its receipt of any such abstract, manuscript or presentation in which to notify Alvogen in writing of its approval or any
specific objections to the disclosure. In the event that Pfenex has a reasonable basis for objecting to the disclosure, it shall object in writing (with the basis therefor) within such ten (10) day period, and Alvogen will not submit the
publication or abstract or make the presentation containing the objected-to information until the Parties have agreed to the content of the proposed disclosure, and if the Parties are unable to agree, the
matter shall be referred to the Executive Steering Committee. Alvogen shall delete from the proposed disclosure any Confidential Information of Pfenex upon the request of Pfenex. Alvogen shall delay any proposed disclosure to allow Pfenex sufficient
time for the drafting and filing of a patent application directed to any patentable subject matter identified by Pfenex in such proposed disclosure. The Parties agree to take all reasonable steps to address and resolve a notice of objection by
Pfenex within thirty (30) days of receipt of such notice. Once any such abstract or manuscript is accepted for publication, Alvogen shall provide Pfenex with a copy of the final version of the manuscript or abstract. 

ARTICLE IX 

REPRESENTATIONS, WARRANTIES AND COVENANTS 

Section 9.1    Representations and Warranties of Pfenex. Pfenex hereby represents and warrants to Alvogen as
of the Effective Date as follows: 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

36 

 (a)    Organization and Good Standing. Pfenex is duly
incorporated, validly existing and in good standing under the laws of Delaware, with all requisite corporate power and authority required to conduct its business as presently conducted. 

(b)    Authority. Pfenex has all requisite corporate power and authority to execute and deliver this Agreement and
to perform all of its obligations hereunder. The execution and delivery by Pfenex of this Agreement and the performance by Pfenex of its obligations hereunder have been duly authorized by all requisite corporate action of Pfenex and no other action
on the part of Pfenex or its stockholders or board of directors is necessary to authorize the execution, delivery or performance by Pfenex of this Agreement. 

(c)    Valid and Binding Agreement. This Agreement has been duly executed and delivered by Pfenex and constitutes
the legal, valid and binding obligation of Pfenex, enforceable against Pfenex in accordance with its terms, except to the extent that the enforceability thereof may be limited by (i) applicable bankruptcy, insolvency, fraudulent conveyance,
reorganization, moratorium or similar laws from time to time in effect affecting generally the enforcement of creditors’ rights and (ii) general principles of equity. 

(d)    Non-Contravention. The execution and delivery of this Agreement by Pfenex and the performance by Pfenex of
its obligations hereunder, including the grant of the Product License pursuant to Article II, does not and will not (i) violate any provision of the organizational documents of Pfenex, (ii) conflict with or violate any Applicable Law
applicable to Pfenex or any of its assets or properties, (iii) require any permit, authorization, consent, approval, exemption or other action by, notice to or filing with any entity or Governmental Authority (other than as expressly
contemplated hereby), (iv) violate, conflict with, result in a material breach of, or constitute (with or without notice or lapse of time or both) a material default under, or an event which would give rise to any right of notice, modification,
acceleration, payment, cancellation or termination under, or in any manner release any party thereto from any obligation under, any permit or contract to which Pfenex is a party or by which any of its properties or assets are bound, in each case
that are necessary for Pfenex’s performance of its obligations or grant of rights to Alvogen hereunder, or (v) result in the creation or imposition of any Lien on any part of the properties or assets of Pfenex. 

(e)    No Commissions. Pfenex is not under any obligation to pay any commission or similar fee in connection with
the transactions contemplated by this Agreement for which Alvogen shall be made responsible or shall become obligated to pay for any reason. 

(f)    No Litigation. There is no Action against Pfenex or any of its Affiliates or that has been brought by Pfenex
or any of its Affiliates which is pending or, to Pfenex’s Knowledge, threatened in writing, and, to Pfenex’s Knowledge, there is no investigation of Pfenex or its Affiliates pending before any Governmental Authority, in each case
(i) that would reasonably be expected to prevent the consummation of the transactions contemplated by this Agreement, (ii) that would reasonably be expected to materially adversely affect Pfenex’s development activities for Product in
the Territory, the Product in the Territory or the conduct of the Business in the Territory, or (iii) that would reasonably be expected to materially adversely 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

37 

 
affect reimbursement for Product under any program funded by a Governmental Authority in the Territory. 

(g)    Regulatory Matters; Compliance with Law. Pfenex and its Affiliates are, and have been at all times, in
compliance in all respects with Applicable Laws that are or were applicable to its conduct of the Business in the Territory or its ownership or use of Product in the Territory, and hold and are operating in compliance with such Registrations of the
FDA as are required for the conduct of the Business in the Territory, except where any non-compliance with Applicable Law or failure to hold or operate in compliance with such Registrations would not
reasonably be expected to have, individually or in the aggregate, a material adverse effect on Product in the Territory, the conduct of the Business in the Territory or Pfenex’s ability to perform its obligations hereunder. No event has
occurred which allows, or after notice or lapse of time would allow, revocation or termination of any such Registration except where the occurrence of such event would not reasonably be expected to have, individually or in the aggregate, a material
adverse effect on Product in the Territory, the conduct of the Business in the Territory or Pfenex’s ability to perform its obligations hereunder. The clinical, pre-clinical and other studies and tests of
Product conducted by, on behalf of or sponsored by Pfenex were and, if still pending, are being conducted in all material respect in accordance with standard medical and scientific research procedures and all Applicable Laws, including but not
limited to the Federal Food, Drug and Cosmetic Act and its applicable implementing regulations at 21 C.F.R. Parts 50, 54, 56, 58 and 312. No Governmental Authority has notified Pfenex or any of its Affiliates or, to Pfenex’s Knowledge,
subcontractors in writing that any activities in its conduct of the Business in the Territory are in violation of any Applicable Law or the subject of any Action or investigation, except where any violation of Applicable Law or any Action or
investigation would not reasonably be expected to have, individually or in the aggregate, a material adverse effect on Product in the Territory, the conduct of the Business in the Territory or Pfenex’s ability to perform its obligations
hereunder. 
 (h)    No Competing Products. Neither Pfenex nor its Affiliates currently owns, in-licenses or is in the process of in-licensing a Competing Product in any stage of development or Commercialization or currently has any ongoing program to develop or
acquire such a Competing Product. Pfenex has not out-licensed or otherwise granted rights to any Third Party under any Pfenex Technology with respect to Product or a Competing Product, in each case in the
Territory. 
 (i)    Pfenex Technology. 

(i)    Pfenex Controls the Pfenex Patents listed in the Product Memo, and Pfenex has not granted any rights to any Third
Party under the Pfenex Technology that conflicts with the rights granted to Alvogen hereunder. None of the Pfenex Patents is or has been the subject of any pending Action or, to Pfenex’s Knowledge, the subject of any threatened Action with
respect to inventorship challenges, interferences, reissues, reexaminations, inter partes review, post grant review, supplemental review, invalidation, opposition, cancellation, abandonment or any order or decree of any Governmental Authority
restricting the use of such Pfenex Patent in connection with Product. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

38 

 (ii)    Neither Pfenex nor any of Pfenex’s Affiliates has received
written notice from any Third Party claiming that the practice of the Pfenex Technology or its conduct of the Business infringes any patent claim of any Third Party or misappropriates or makes any unauthorized use of any Intellectual Property of any
Third Party. 
 (iii)    To Pfenex’s Knowledge, no Third Party is infringing, misappropriating or making any
unauthorized use of any Pfenex Technology in the Territory with respect to a Competing Product, and there is no Action or investigation in contemplation of an Action by Pfenex pending or threatened against any Third Party related to the Pfenex
Technology in the Territory with respect to a Competing Product. 
 (iv)    None of the Pfenex Technology is subject to
any outstanding decree, order, judgment or stipulation of a Governmental Authority against Pfenex, its Affiliates or, to Pfenex’s Knowledge, any other Person restricting in any manner the conduct of the Business. 

(v)    There are no contracts pursuant to which Pfenex in-licenses or otherwise
has rights under any Intellectual Property of any Third Party that is material to the Business or the operation thereof.  

(vi)    To Pfenex’s Knowledge, Pfenex owns or has received all licenses or otherwise has sufficient rights with
respect to the Pfenex Technology necessary for Pfenex to comply with the terms of this Agreement. 
 (vii)    The
Pfenex Expression Technology is not necessary for the conduct of the Business, but in the event it is necessary, Pfenex has the right to license or sublicense the Pfenex Expression Technology to Alvogen or any of its Affiliates, without any
obligation of Alvogen to make any payment of money, royalties or other consideration in connection with the operation of the Business, including Alvogen’s operation thereof after termination of this Agreement pursuant to
Section 10.2(a)(iii); and 
 (viii)    Pfenex has taken commercially reasonable steps to protect and preserve the
confidentiality of all confidential information included in the Pfenex Patents and has taken legally adequate measures to protect the Know-How that is Controlled by Pfenex that is or would be material to the
Business, in the case of all such steps or measures, that are consistent with the practices of the biotechnology industry, and all of Pfenex’s employees, contractors and consultants who were or are engaged in the development or invention of any
Pfenex Technology have entered into written agreements with Pfenex validly and irrevocably assigning to Pfenex all rights, title and interests in and to such Pfenex Technology (or all such rights, title and interests have or are vested in Pfenex as
a matter of law). 
 (j)    Debarment. Neither Pfenex nor any of its Affiliates, nor, to Pfenex’s Knowledge,
any of its subcontractors, employees or agents has ever been, is currently, or is the subject of a debarment proceeding that could lead to that party becoming, as applicable, a Debarred Entity or Debarred Individual. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

39 

 (k)    No Adverse Findings. To Pfenex’s Knowledge, there is
no event, discovery, fact, development, change or circumstance which, individually or in the aggregate, has had or could reasonably be expected to have a material adverse effect, only taking into consideration information reasonably available as of
the Effective Date, on the Development Plan or on the ability to obtain Regulatory Approval for, manufacture, commercialize, promote, import, market, offer for sale, sell or distribute Product in the Territory during the Term. To Pfenex’s
Knowledge, Pfenex has disclosed to Alvogen all material information (or such information is available in Pfenex’s public filings) with respect to the Product and the Business. 

Section 9.2    Representations and Warranties of Alvogen. Alvogen hereby represents and warrants to Pfenex as
of the Effective Date as follows: 
 (a)    Organization and Good Standing. Alvogen is duly incorporated, validly
existing and in good standing under the laws of Malta, with all requisite corporate power and authority required to conduct its business as presently conducted; 

(b)    Authority. Alvogen has all requisite corporate power and authority to execute and deliver this Agreement and
to perform all of its obligations hereunder. The execution and delivery by Alvogen of this Agreement and the performance by Alvogen of its obligations hereunder have been duly authorized by all requisite corporate action of Alvogen and no other
action on the part of Alvogen or its stockholders or board of directors is necessary to authorize the execution, delivery or performance by Alvogen of this Agreement; 

(c)    Valid and Binding Agreement. This Agreement has been duly executed and delivered by Alvogen and constitutes
the legal, valid and binding obligation of Alvogen, enforceable against Alvogen in accordance with its terms, except to the extent that the enforceability thereof may be limited by (i) applicable bankruptcy, insolvency, fraudulent conveyance,
reorganization, moratorium or similar laws from time to time in effect affecting generally the enforcement of creditors’ rights, and (ii) general principles of equity; 

(d)    Non-Contravention. The execution and delivery of this Agreement by
Alvogen and the performance by Alvogen of its obligations hereunder does not and will not (i) violate any provision of the organizational documents of Alvogen, (ii) conflict with or violate any Applicable Law applicable to Alvogen or its
assets or properties, (iii) require any permit, authorization, consent, approval, exemption or other action by, notice to or filing with any entity or Governmental Authority (other than as expressly contemplated hereby), (iv) violate,
conflict with, result in a material breach of, or constitute (with or without notice or lapse of time or both) a material default under, or an event which would give rise to any right of notice, modification, acceleration, payment, cancellation or
termination under, or in any manner release any party thereto from any obligation under, any permit or contract to which Alvogen is a party or by which any of its properties or assets are bound, in each case that are necessary for Alvogen’s
performance of its obligations or grant of rights to Pfenex hereunder, or (v) result in the creation or imposition of any Lien on any part of the properties or assets of Alvogen; 

(e)    No Commissions. Alvogen is not under any obligation to pay any commission or similar fee in connection with
the transactions contemplated by this Agreement for which Pfenex shall be made responsible or shall become obligated to pay for any reason; 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

40 

 (f)    No Litigation. There is no Action against Alvogen or any
of its Affiliates or that has been brought by Alvogen or any of its Affiliates which is pending or, to Alvogen’s Knowledge, threatened in writing, and, to Alvogen’s Knowledge, there is no investigation of Alvogen or its Affiliates pending
before any Governmental Authority, in each case (i) that would reasonably be expected to prevent the consummation of the transactions contemplated by this Agreement, (ii) that would reasonably be expected to materially adversely affect the
Product or the conduct of the Business, or (iii) that would reasonably be expected to materially adversely affect reimbursement for Product under any program funded by a Governmental Authority; 

(g)    Debarment. Alvogen represents and warrants that neither it nor any of its Affiliates, nor, to Alvogen’s
Knowledge, any of its Subcontractors, employees or agents has ever been, is currently, or is the subject of a debarment proceeding that could lead to that party becoming, as applicable, a Debarred Entity or Debarred Individual; and 

(h)    No Competing Products. Neither Alvogen nor its Affiliates currently owns or is in the process of in-licensing a Competing Product in any stage of development or Commercialization or currently has any ongoing program to develop or acquire such a Competing Product. 

Section 9.3    Covenants. 

(a)    Debarment by Pfenex. If, during the Term, Pfenex or any of its Affiliates, subcontractors, employees or
agents becomes or is the subject of any Regulatory Agency investigation or debarment proceeding that could lead to Pfenex or such Affiliate, subcontractor, employee or agent, as applicable, becoming a Debarred Entity or Debarred Individual, Pfenex
shall immediately notify Alvogen, and, if such occurrence materially and adversely affects Pfenex’s ability to perform its obligations hereunder or Alvogen’s ability to develop, obtain NDA Approval for, manufacture or Commercialize,
Product in the Territory, then such occurrence shall be deemed a material breach of this Agreement and Alvogen shall have the right to terminate this Agreement pursuant to Section 10.2(b)(i). 

(b)    Debarment by Alvogen. If, during the Term, Alvogen or any of its Affiliates, Subcontractors, employees or
agents becomes or is the subject of any Regulatory Agency investigation or debarment proceeding that could lead to Alvogen or such Affiliate, Subcontractor, employee or agent, as applicable, becoming a Debarred Entity or Debarred Individual, Alvogen
shall immediately notify Pfenex, and if such occurrence materially and adversely affects Alvogen’s ability to perform its obligations hereunder, then such occurrence shall be deemed a material breach of this Agreement and Pfenex shall have the
right to terminate this Agreement pursuant to Section 10.2(a)(i). 
 (c)    Assignment of Product
Inventions. Each Party shall maintain valid and enforceable agreements with all persons and entities acting by or on behalf of such Party or its Affiliates under this Agreement which require such Persons to assign to such Party their entire
right, title and interest in and to all Product Inventions made by such Person in connection with their activities under this Agreement. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

41 

 Section 9.4    Disclaimer of Warranties. EXCEPT AS SET FORTH
IN SECTIONS 9.1 AND 9.2, PFENEX AND ALVOGEN EXPRESSLY DISCLAIM ANY WARRANTIES, EXPRESS, IMPLIED, STATUTORY OR OTHERWISE, WITH RESPECT TO THE SUBJECT MATTER OF THIS AGREEMENT (INCLUDING THE PRODUCT AND PFENEX TECHNOLOGY), INCLUDING ANY WARRANTY OF
MERCHANTABILITY, NONINFRINGEMENT, OR FITNESS FOR A PARTICULAR PURPOSE. 
 Section 9.5    Insurance. 

(a)    To provide sufficient protection to both Pfenex and Alvogen, Pfenex and Alvogen will each, individually, at its own
cost and expense, obtain and maintain in full force and effect, during the Term, the following lines of insurance and specified limits: 

(i)    Commercial General Liability (including Premises Operations). The policy must be on an occurrence form and
include the following limits: [***]. 
 (ii)    Commercial Umbrella Liability. This policy must include the
following limits: [***]. 
 (iii)    Product Liability Insurance. [***]. 

(b)    Insurance for each Party shall be primary and non-contributory to any
insurance or self-insurance maintained by the other Party. Each Party shall be named as an additional insured within the other Party’s products liability and general liability insurance policies; provided, that such additional insured status
will apply solely to the extent of the insured Party’s indemnity obligations under this Agreement. All of the aforementioned lines can be satisfied via any combination of primary, excess or umbrella insurance coverage. Upon execution of this
Agreement and upon written request thereafter, each Party shall provide the other Party with an insurance certificate evidencing the required insurance limits in this Section 9.5. Each Party shall provide thirty (30) days’ notice to
the other Party prior to any cancellation or material change to the required insurance policies. All insurance companies utilized by a Party to meet the requirements herein must have an A.M. Best Rating of
“A-, VII” or better. Each Party may self-insure all or any portion of the insurance requirements in this Section 9.5 during any given Annual Period, as long as such self-insuring Party has
earnings before interest, tax depreciation and amortization expense of at least $100,000,000 on the basis of such Party’s Accounting Standards for the immediately preceding Annual Period. Additional insured status obligations will operate in
the same manner, whether insurance is carried through third parties or through self-insurance. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

42 

 ARTICLE X 

TERM; TERMINATION 

Section 10.1    Term. This Agreement shall become effective on the Effective Date and continue until the
earlier of (i) ten (10) years following the First Commercial Sale in the Territory, or (ii) the date this Agreement is terminated in accordance with Section 10.2 (such shorter period, the “Term”). 

Section 10.2    Termination. 

(a)    Notwithstanding anything contained herein to the contrary, Pfenex may terminate this Agreement in its entirety: 

(i)    upon ninety (90) days’ prior written notice to Alvogen if Alvogen has materially breached this Agreement
(with the specific nature of such breach being identified in such notice) and Alvogen fails to cure such breach within such ninety (90) day period; provided, however, that the failure to timely pay any payment obligation that is subject to a
good faith Dispute shall not be deemed a material breach of this Agreement; 
 (ii)    immediately upon written notice
to Alvogen following, in the case of insolvency, the appointment of a receiver by a court of competent jurisdiction with respect to the assets of Alvogen, the assignment for the benefit of creditors of the assets of Alvogen or the entry of an order
for relief (or similar ruling or proceeding) under applicable bankruptcy or insolvency laws against Alvogen; or 

(iii)    upon written notice to Alvogen based upon Safety Reasons. If Alvogen disputes the existence of such Safety
Reasons, such dispute shall be referred to the Executive Steering Committee and Pfenex’s right to terminate this Agreement shall be stayed during the pendency of such dispute resolution process. 

(b)    Notwithstanding anything contained herein to the contrary, Alvogen may terminate this Agreement in its entirety:

 (i)    upon ninety (90) days’ prior written notice to Pfenex, if Pfenex has materially breached of this
Agreement (with the specific nature of such breach being identified in such notice) and Pfenex fails to cure such breach within such ninety (90) day period; 

(ii)    immediately upon written notice to Pfenex following, in the case of insolvency, the appointment of a receiver by
a court of competent jurisdiction with respect to the assets of Pfenex, the assignment for the benefit of creditors of the assets of Pfenex or the entry of an order for relief (or similar ruling or proceeding) under applicable bankruptcy or
insolvency laws against Pfenex; 
 (iii)    upon written notice to Pfenex based upon Safety Reasons. If Pfenex disputes
the existence of such Safety Reasons, such dispute shall be referred to the Executive Steering Committee and Alvogen’s right to terminate this Agreement shall be stayed during the pendency of such dispute resolution process; 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

43 

 (iv)    upon sixty (60) days’ prior written notice to Pfenex
given anytime thirty six (36) months after the Effective Date, provided that as of the date of such notice the Transfer Effective Date has not occurred; 

(v)    upon sixty (60) days’ prior written notice to Pfenex, [***]; or 

(vi)    upon twelve (12) months’ prior written notice to Pfenex for any or no reason, beginning one
(1) year after the First Commercial Sale in the Territory. 
 Section 10.3    General Effects of Expiration
or Termination. 
 (a)    Except as otherwise expressly provided in this Article X, all rights and obligations of the
Parties under this Agreement shall terminate upon expiration or termination of this Agreement for any reason. 

(b)    Notwithstanding anything contained in this Agreement to the contrary, in no event shall the expiration or
termination of this Agreement affect any Party’s obligation to pay any amounts owed to any other Party as of the time of such expiration or termination or release either Party of any other obligation or liability which, at the time of such
expiration or termination, has already accrued to the other Party or which is attributable to a period prior to such expiration or termination. 

(c)    Upon the expiration or termination of this Agreement, Articles I, XI and XII and Sections 3.3(d) (for the period
specified therein), 4.4 – 4.7 (inclusive, with respect to the period prior to the effective date of termination), 4.8 (for the period specified therein), 4.10 (with respect to the period prior to the effective date of termination), 5.5 (with
respect to any Product sold before termination), 6.2, 8.1 (for a period of five (5) years after the effective date of termination) 8.6 (for a period of twelve (12) months after the effective date of termination), 9.4, 9.5(a)(iii) (for the
period specified therein), 10.3, 10.4 and 10.5 (in the circumstances provided therein) shall survive and remain in effect. 

Section 10.4    Additional Effects of Expiration or Termination. If this Agreement expires or is terminated
pursuant to Section 10.2(a)(i) (Alvogen breach), Section 10.2(a)(ii) (Alvogen Insolvency), Section 10.2(b)(ii) (Pfenex Insolvency), Section 10.2(b)(iv) (Late Transfer Effective Date), Section 10.2(b)(v) (Excessive Regulatory
Costs), or Section 10.2(b)(vi) (One Year Notice), then: 
 (a)    Transition Assistance. (i) Alvogen
shall cooperate with Pfenex or its designee(s) to facilitate the transition of the development and manufacture, if any, and Commercialization of Product in the Territory to Pfenex or its designee(s) after the notice of termination of this Agreement,
(ii) upon request by Pfenex, Alvogen shall transfer to Pfenex some or all quantities of any unlabeled Product in its or its Affiliates’ possession or control, within thirty (30) days of Alvogen’s receipt of such request;
provided, however, that Pfenex shall pay Alvogen the actual cost that Alvogen incurred to acquire the quantities so provided to Pfenex, and (iii) upon Pfenex’s request, the Executive Steering Committee shall promptly (but in
any event not more than thirty (30) days after such request) meet and establish a transition plan to implement the transition of the development, manufactures and Commercialization of Product 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

44 

 
in the Territory to Pfenex or its designee(s). Accordingly, Alvogen shall take all actions reasonably necessary, and cooperate with Pfenex or its designee(s), to facilitate a smooth, orderly and
prompt transition so that Pfenex or its applicable designee is reasonably enabled and has control over any ongoing development, manufacture and Commercialization of Product in the Territory. 

(b)    Regulatory Materials. 

(i)    Alvogen shall promptly assign and transfer to Pfenex all Regulatory Materials for Product in the Territory that are
held or controlled by or under authority of Alvogen or its Affiliates, and shall take such actions and execute such other instruments, assignments and documents as may be necessary to effect the transfer of rights under such Regulatory Materials to
Pfenex and Pfenex shall assume all obligations, including pharmacovigilance obligations, under all Applicable Laws with regard to such Regulatory Materials; 

(ii)    Alvogen shall cause each of its Affiliates to transfer all such Regulatory Materials to Pfenex; 

(iii)    If Applicable Law prevents or delays the transfer of ownership or possession of Regulatory Materials for Product
to Pfenex, Alvogen shall grant, and does hereby grant, to Pfenex an exclusive (except as to Alvogen to the extent necessary to comply with Applicable Laws) and irrevocable right of access and reference to such Regulatory Materials, and shall
cooperate fully to make the benefits of such Regulatory Materials available to Pfenex or its designee(s); and 

(iv)    Alvogen shall provide to Pfenex copies of all such Regulatory Materials. 

(c)    Redirection of Subdomain Name. With respect to any subdomain name owned and used by Alvogen or its Affiliate
in connection with the Product Trademark or the Product as of the expiration of the Term or effective date of termination: (i) Alvogen shall, as soon as practicable thereafter, post a notice mutually consented to by the Parties, on the webpage
associated with each such subdomain name, advising visitors that applicable Product is now marketed by Pfenex or its Affiliates (or another statement agreed to by the Parties), and shall otherwise leave such Product webpage intact pending receipt of
a redirection request from Pfenex; and (ii) Alvogen shall, as soon as practicable following receipt of a request from Pfenex, implement an automatic redirect taking visitors from the internet address (url) associated with each such subdomain to
a Pfenex-controlled website designated by Pfenex. In addition, with respect to any internet address (url) specific to the Product Trademark or Product and associated contents, Alvogen shall at Pfenex’s request assign the same to Pfenex or its
designee. 
 (d)    Costs and Expenses. Except as expressly provided herein, each Party shall perform its
obligations under this Section 10.4 at its own costs. 
 Section 10.5    Additional Effects of Specific
Terminations. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

45 

 (a)    If this Agreement is terminated pursuant to any of Section
10.2(a)(iii), Section 10.2(b)(i), Section 10.2(b)(ii), Section 10.2(b)(iii) prior to the Transfer Effective Date or pursuant to Section 10.2(b)(iv), then Pfenex shall, within sixty (60) Business Days of the effective date of termination, remit
payment to Alvogen the amount of Two Million Five Hundred Thousand Dollars ($2,500,000). 
 (b)    If this Agreement is
terminated pursuant to Section 10.2(a)(iii) and Pfenex has exercised its final resolution authority under Section 7.4(b)(i) with respect to the underlying Safety Reasons, then (i) no payments under Section 4.5 shall be due for
any Gross Profit (or associated Net Sales) occurring after the effective date of such termination, (ii) the Product License shall become perpetual and irrevocable (provided, however, that such irrevocability shall not limit the remedies
available to any Party hereunder for breach of this Agreement), (iii) Pfenex shall have no obligation to indemnify Alvogen under clause (f) of Section 11.1 with respect to any activities after the effective date of such termination,
and (iv) Alvogen’s indemnification obligations under clauses (e) and (f) of Section 11.2 shall not be subject to the limitations set forth in Section 11.4. and in the case of clause (f) no portion of such Losses shall
be allocated to Pfenex under Section 11.5. 
 ARTICLE XI 

INDEMNIFICATION AND LIABILITY LIMITS 

Section 11.1    Indemnification by Pfenex. Pfenex shall indemnify, defend and hold harmless (collectively,
“Indemnify”) Alvogen, its Affiliates and its and their respective directors, officers, employees, agents and representatives (the “Alvogen Indemnitees”) from and against any and all losses, damages, liabilities,
penalties, costs and expenses (including reasonable attorneys’ fees and court costs) (collectively, “Losses”), resulting from suits, claims, actions and demands, in each case, brought by a Third Party (each, a “Third
Party Claim”) against any Alvogen Indemnitee arising out of (a) any breach by Pfenex of any of its obligations or representations and warranties hereunder, (b) the negligence, recklessness or willful misconduct by Pfenex or any of
its Affiliates or any of their respective officers, directors, employees, agents or representatives in connection with the performance of this Agreement, (c) any violation by Pfenex or any of its Affiliates or any of their respective officers,
directors, employees, agents or representatives of any Applicable Law applicable to the performance of Pfenex’s obligations under this Agreement, (d) development of the Product, regulatory actions taken on or prior to the Transfer
Effective Date, actions performed pursuant to Section 3.1, or the performance under this Agreement, in each case by Pfenex or any of its employees, agents, or Affiliates, (e) Commercialization of the Product by Pfenex or any of its
employees, agents, Affiliates or licensees outside of the Territory, or (f) the allocated portion (allocated in accordance with Section 11.5) of any claims based upon product liability, bodily injury, death or property damage relating to
Product sold in the Territory during the Term. Pfenex’s obligation to Indemnify the Alvogen Indemnitees pursuant to this Section 11.1 shall not apply to the extent such Losses are attributable to a cause or event described in
Section 11.2. This Section 11.1 shall not apply with respect to Taxes other than any Taxes that represent losses, claims, damages, etc. arising from any non-Tax claim. 

Section 11.2    Indemnification by Alvogen. Alvogen shall Indemnify Pfenex, its Affiliates and its and their
respective directors, officers, employees, agents and representatives (the “Pfenex Indemnitees”) from and against any and all Losses resulting from Third Party Claims against any Pfenex Indemnitee arising out of (a) any breach
by Alvogen of any of its obligations or representations and warranties hereunder, (b) the negligence, recklessness or 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

46 

 
willful misconduct by Alvogen or any of its Affiliates or any of their respective officers, directors, employees, agents or representatives in connection with the performance of this Agreement,
(c) any violation by Alvogen or any of its Affiliates and any of their respective officers, directors, employees, agents or representatives of any Applicable Laws applicable to the performance of Alvogen’s obligations under this Agreement,
(d) regulatory actions taken after the Transfer Effective Date, actions performed pursuant to Section 3.2, or the performance under this Agreement, in each case by Alvogen or any of its employees, agents, or Affiliates,
(e) Commercialization of Product by Alvogen or any of its employees, agents, Affiliates or sublicensees inside of the Territory (other than claims based upon product liability, bodily injury, death or property damage relating to Product, which
are allocated in clause (f) of this Section 11.2 and clause (f) of Section 11.1), or (f) the allocated portion (allocated in accordance with Section 11.5) of any claims based upon product liability, bodily injury, death
or property damage relating to Product sold in the Territory during the Term. Alvogen’s obligation to Indemnify the Pfenex Indemnitees pursuant to this Section 11.2 shall not apply to the extent such Losses are attributable to a cause or
event described in Section 11.1. This Section 11.2 shall not apply with respect to Taxes other than any Taxes that represent losses, claims, damages, etc. arising from any non-Tax claim. 

Section 11.3    Indemnification Procedure. 

(a)    The Party seeking indemnification under this Article XI (the “Indemnified Party”) agrees to give
prompt written notice (the “Indemnification Notice”) to the Party against whom indemnity is sought (the “Indemnifying Party”) of the assertion of any Third Party Claim, or the commencement of any proceeding in
respect of which indemnity may be sought under this Article XI; provided that the failure of an Indemnified Party to promptly notify the Indemnifying Party on a timely basis will not relieve the Indemnifying Party of any liability that it may have
to the Indemnified Party unless and to the extent the Indemnifying Party demonstrates that it is materially prejudiced by the Indemnified Party’s failure to give timely notice. 

(b)    If the Indemnifying Party does not object to any claim or claims made in the Indemnification Notice in a written
objection (the “Indemnification Objection”) prior to the expiration of twenty (20) Business Days from the Indemnifying Party’s receipt of the Indemnification Notice, the Indemnifying Party shall be deemed not to object to
the information contained within the Indemnification Notice. If the Indemnifying Party delivers an Indemnification Objection within such twenty (20) Business Day period, the Indemnifying Party and the Indemnified Party shall attempt in good
faith to resolve the dispute for twenty (20) Business Days after the Indemnifying Party’s receipt of such Indemnification Objection. If no resolution is reached, the dispute shall be resolved in accordance with the provisions of
Section 12.4 and Section 12.5. 
 (c)    The Indemnifying Party, if it so elects, may assume and control the
defense of a Third Party Claim at the Indemnifying Party’s expense and shall consult with the Indemnified Party with respect thereto, including the employment of counsel reasonably satisfactory to the Indemnified Party; provided, however, that
the Indemnifying Party shall not have the right to assume control of such defense if the claim that the Indemnifying Party seeks to 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

47 

 
assume control of (i) seeks material non-monetary relief, or (ii) involves criminal or quasi-criminal allegations; provided further that Alvogen
shall be entitled to assume and control (subject to Pfenex having the right to participate and comment) the defense of Third Party Claims relating to clause (f) of Section 11.2 and clause (f) of Section 11.1) as if it was the
Indemnifying Party for such claim. If the Indemnifying Party is permitted to assume and control the defense of a Third Party Claim and elects to do so, the Indemnified Party shall have the right to employ counsel separate from counsel employed by
the Indemnifying Party in any such action and to participate in the defense thereof, but the fees and expenses of such counsel employed by the Indemnified Party shall be at the expense of the Indemnified Party unless (A) the Indemnifying Party
has specifically agreed in writing otherwise, or (B) the Indemnifying Party has failed to assume the defense and employ counsel (in which case the fees and expenses of the Indemnified Party’s counsel shall be paid by the Indemnifying Party
if the Indemnifying Party otherwise has an obligation to indemnify the Indemnified Party for the related Third Party Claim). If the Indemnifying Party has assumed the defense of a Third Party Claim in accordance with the terms hereof, the
Indemnifying Party may not enter into a settlement or consent to any judgment without the prior written consent of the Indemnified Party unless (I) such settlement or judgment involves monetary damages only, all of which will be paid, without
limitation, by the Indemnifying Party, and no admission of fault or culpability on behalf of any Indemnified Party, and (II) a term of the settlement or judgment is that the Person or Persons asserting such claim unconditionally and irrevocably
release all Indemnified Parties from all liability with respect to such claim; otherwise, the consent of the Indemnified Party shall be required in order to enter into any settlement of, or consent to the entry of a judgment with respect to, any
claim (which consent shall not be unreasonably withhold, delayed or conditioned). If the Indemnifying Party does not assume or is not controlling the defense of a Third Party Claim for any reason, then the Indemnified Party may retain counsel of its
own choosing, at the expense of the Indemnifying Party, and assume and control the defense of such Third Party Claim, and the Indemnifying Party shall have the right to employ counsel separate from counsel employed by the Indemnified Party in any
such action and to participate in the defense thereof, but the fees and expenses of such counsel employed by the Indemnifying Party shall be at the expense of the Indemnifying Party. The Indemnifying Party shall have no obligations with respect to
any Losses resulting from the Indemnified Party’s admission, settlement or other communication without the prior written consent of the Indemnifying Party (which shall not be unreasonably withheld, delayed or conditioned). 

Section 11.4    Limitations on Liability. Notwithstanding any provision of this Agreement to the contrary, any
claims an Indemnified Party makes under this Article XI will be limited as follows (except as provided in Section 10.5(b)): 

(a)    Annual Deductible. The Alvogen Indemnitees shall only be entitled to indemnification pursuant to this
Article XI (excluding claims made under clause (f) of Section 11.2 and clause (f) of Section 11.1) for Losses incurred in a given Annual Period to the extent the aggregate amount of such Losses incurred by the Alvogen Indemnitees
in such Annual Period and for which the Alvogen Indemnitees are entitled to indemnification pursuant to this Article XI (excluding Losses relating to clause (f) of Section 11.2 and clause (f) of Section 11.1) exceeds 1% of the
aggregate amount paid by Alvogen to Pfenex in such Annual Period. The Pfenex Indemnitees shall only be entitled to indemnification pursuant to this Article XI (excluding 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

48 

 
claims made under clause (f) of Section 11.2 and clause (f) of Section 11.1) for Losses incurred in a given Annual Period to the extent the aggregate amount of such Losses
incurred by the Pfenex Indemnitees in such Annual Period and for which the Pfenex Indemnitees are entitled to indemnification pursuant to this Article XI (excluding Losses relating to clause (f) of Section 11.2 and clause (f) of
Section 11.1) exceeds 1% of the aggregate amount paid by Alvogen to Pfenex hereunder in such Annual Period. 

(b)    Annual Cap. The aggregate amount of Losses incurred by the Alvogen Indemnitees in a given Annual Period for
which the Alvogen Indemnitees shall be entitled to indemnification pursuant to this Article XI (excluding Loss claims made under clause (f) of Section 11.2 and clause (f) of Section 11.1) shall be limited to an amount equal to
[***]. The aggregate amount of Losses incurred by the Pfenex Indemnitees in a given Annual Period for which the Pfenex Indemnitees shall be entitled to indemnification pursuant to this Article XI (excluding Loss claims made under clause (f) of
Section 11.2 and clause (f) of Section 11.1) shall be limited to an amount equal to [***]. 

(c)    No Special or Indirect Damages. Except as arising out of a failure of a Party to pay any amount owed
hereunder, or arising as the result of the fraud by a Party, or arising from breach of a Party’s confidentiality obligations in Sections 8.1-8.3 or obligations under Section 2.4, neither Party, nor
any of their respective Affiliates, directors, members, officers, employees, subcontractors or agents, shall have, under any legal theory (including contract, negligence and tort liability), any liability to any other Party for any consequential,
special, indirect, incidental or punitive damages arising out of or related to breach of this Agreement. 

(d)    Net of Insurance, Third-Party Recoveries and Tax Benefits. All Losses for which any Indemnified Party would
otherwise be entitled to indemnification under this Article XI shall be reduced by the amount of insurance proceeds actually received by an Indemnified Party from an insurance carrier, Tax benefits, indemnification payments and other third-party
recoveries to which any Indemnified Party is entitled in respect of any Losses incurred by such Indemnified Party. In the event any Indemnified Party or any of its Affiliates is entitled to any insurance proceeds, Tax benefits, indemnity payments or
any third party recoveries in respect of any Losses (or any of the circumstances giving rise thereto) for which such Indemnified Party is entitled to indemnification pursuant to this Article XI, such Indemnified Party shall use commercially
reasonable efforts to obtain, receive or realize such proceeds, benefits, payments or recoveries. In the event that any such insurance proceeds, indemnity payments or other third-party recoveries (but not Tax benefits, which shall only result in a one-time reduction in Losses at the time provided for below) are obtained, received or realized by an Indemnified Party subsequent to receipt by such Indemnified Party of any indemnification payment hereunder in
respect of the claims to which such insurance proceeds, indemnity payments or other third-party recoveries relate, appropriate refunds shall be made promptly by the relevant Indemnified Parties of all or the relevant portion of such indemnification
payment. For purposes of this Section 11.4(d), any Indemnified Party will be deemed to realize a Tax benefit in respect of any Losses incurred to the extent that the liability for cash income Taxes of the Indemnified Party in the taxable period
during which such Losses are incurred (calculated with such Losses excluded) exceeds the actual liability for cash income 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

49 

 
Taxes of the Indemnified Party for such taxable period (calculated with such Losses included). If any Indemnified Party receives any indemnification payment pursuant to this Article XI, at the
election of the Indemnifying Party, such Indemnified Party shall assign to the Indemnifying Party all of its claims for recovery against third Persons as to such Losses, whether by insurance coverage, contribution claims, subrogation or otherwise
but only up to the amount of such indemnification payment. 
 (e)    Mitigation of Losses. An Indemnified Party
shall use commercially reasonable efforts to mitigate any Losses for which it is entitled to indemnification pursuant to this Article XI. The Indemnifying Party shall have the right, but not the obligation, and shall be afforded the opportunity by
the Indemnified Party to the extent reasonably possible, to take all available steps to minimize Losses for which the Indemnified Party is entitled to indemnification before such Losses actually are incurred by the Indemnified Party. 

Section 11.5    Product Liability Allocation. All Losses relating to the indemnity provisions contained in
clause (f) of Section 11.2 and clause (f) of Section 11.1 shall be allocated between Alvogen and Pfenex such that Pfenex bears the Pfenex Profit Share (as in effect in the Quarterly Period when such Losses were incurred) of such
Losses and Alvogen bears the remainder of such Losses. 
 Section 11.6    Cooperation. The Indemnified Party
and Indemnifying Party shall cooperate in all reasonable respects in connection with the defense of any Third Party Action. At the reasonable request of the Indemnifying Party, each Indemnified Party shall grant the Indemnifying Party and its
representatives all reasonable access to the books, records, employees and properties of such Indemnified Party to the extent reasonably related to the matters to which the applicable indemnification claim relates. All such access shall be granted
during normal business hours and shall be granted under the conditions which shall not unreasonably interfere with the business and operations of such Indemnified Party. Indemnifying Party and the Indemnified Party may, but are not obligated to,
share materials that are privileged or otherwise protected from disclosure under applicable Law. To the extent the defense of any Action presents the need for understanding of materials that are privileged or otherwise protected from disclosure, The
Parties agree to act in good faith in considering entry into a common interest agreement (or similar agreement) that would facilitate these protected materials to be shared in furtherance of defending the Action. 

ARTICLE XII 

MISCELLANEOUS 

Section 12.1    Force Majeure. Neither Party shall be held liable or responsible to the other Party nor be
deemed to have defaulted under or breached this Agreement for failure or delay in fulfilling or performing any term of this Agreement when such failure or delay is caused by or results from the causes beyond the reasonable control of the affected
Party, including: fire, floods, earthquake, tsunami, ice, tornado, hurricane, windstorm, eruption, explosion, sabotage or vandalism, embargoes, war, acts of war (whether war be declared or not), invasion, domestic or foreign terrorist act, act of a
public enemy, insurrections, riots, civil commotions, strikes, lockouts or other labor disturbances, shortages of materials, failure of utilities, acts of God or 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

50 

 
acts, omissions or delays in acting by any Governmental Authority (each, an event of “Force Majeure”); provided that such affected Party shall provide the other Party with prompt
written notice of the circumstances surrounding such a material failure or delay and will use Diligent Efforts to overcome the difficulties created thereby and to resume performance of its obligations as soon as practicable. If the performance of
any such obligation under this Agreement is delayed owing to such a Force Majeure for any continuous period of more than one hundred eighty (180) days, the Parties will consult with respect to an equitable solution, including the possibility of
the mutual termination of this Agreement. For the avoidance of doubt, the occurrence of an event of Force Majeure shall not relieve any Party from fulfilling any obligation required hereunder; rather, the period for performance of such obligation
shall be tolled during the occurrence of such Force Majeure. 
 Section 12.2    Notices. Any notice,
request, approval or consent required or permitted to be given by any Party shall be in writing and shall be to the Parties at the addresses or facsimile number listed below, or such other address or facsimile number as such Party will have last
given by notice to the other Party, and shall be deemed to have been sufficiently given when delivered in person, transmitted by electronic mail (receipt verified) or by express courier service (signature required) or five (5) days after it was
sent by registered mail, return receipt requested (or its equivalent), provided that no postal strike or other disruption is then in effect or comes into effect within two (2) days after such mailing. 

 

			
	If to Pfenex, to:	  	Pfenex Inc.
	 	  	10790 Roselle Street
	 	  	San Diego, CA 92121
	 	  	Attention: Patrick Lucy, Chief Business Officer
	 	  	PKL@Pfenex.com
		
	With a copy to:	  	Wilson Sonsini Goodrich & Rosati
	 	  	650 Page Mill Road
	 	  	Palo Alto, CA 94304
	 	  	Attention: Ian B. Edvalson
	 	  	iedvalson@wsgr.com
		
	If to Alvogen, to:	  	Alvogen Malta Operations Ltd.
	 	  	10 Bloomfield Avenue, Bldg B
	 	  	Pine Brook, NJ 07058
	 	  	Attention: Legal
	 	  	Andrea.Sweet@alvogen.com
		
	With a copy to:	  	Latham & Watkins LLP
	 	  	650 Town Center Drive
	 	  	20th Floor
	 	  	Costa Mesa, CA 92626
	 	  	Attention: David C. Lee
		  	david.lee@lw.com

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

51 

 Section 12.3    Governing Law. This Agreement and all
matters and disputes arising therefrom shall be construed, governed, interpreted and applied in accordance with the laws of the State of New York, without giving effect to any conflicts of laws principles. 

Section 12.4    Internal Dispute Resolution. In the event that a dispute, difference or question arises
pertaining to any matters which are the subject of this Agreement not otherwise resolved in accordance with Section 7.4(b) (a “Dispute”), prior to the initiation of arbitration as described in Section 12.5, the Dispute
shall be submitted to the Chief Executive Officers (or their respective designees) of Alvogen and Pfenex, who shall use their good faith efforts to resolve the Dispute within ten (10) Business Days after notice is provided pursuant to
Section 12.2. If any such Dispute is not resolved by the Chief Executive Officers or their designees within ten (10) Business Days after submission of such Dispute to such officers, then the Dispute shall be resolved in accordance with the
arbitration procedure set forth in Section 12.5. For clarity, Disputes include disagreements regarding (a) the interpretation of this Agreement, and (b) the breach or alleged breach by a Party of its obligations under this Agreement
and associated remedies and damages of a Party in the event of a breach of the Agreement by the other Party (and the structure and payment of any such damages). 

Section 12.5    Arbitration. 

(a)    If the Parties are unable to resolve a Dispute under Section 12.4, then the Parties agree that all Disputes of
any kind or nature (except those described in Section 12.5(c)) shall be resolved exclusively pursuant to the alternative dispute resolution terms and conditions set forth in Exhibit 12.5; provided that judgment upon
any arbitral award may be confirmed and entered by any court having competent jurisdiction over the Parties or their assets. The determination resulting from such alternative dispute resolution shall be final, binding and non-appealable for purposes of this Agreement. Nothing in Section 12.4 or this Section 12.5 shall limit any Party’s right to seek and obtain in any such alternative dispute resolutions any equitable
relief to which such Party is entitled hereunder. 
 (b)    Notwithstanding Section 12.4 and Section 12.5(a),
an application for emergency or temporary injunctive relief by any Party shall not be subject to internal dispute resolution under Section 12.4 or alternative dispute resolution under Section 12.5(a); provided, however, that the remainder
of any such Dispute (beyond the application for emergency or temporary injunctive relief) shall be subject to internal dispute resolution under Section 12.4 and alternative dispute resolution under Section 12.5(a), as applicable. 

(c)    Any Dispute relating to the ownership, scope, validity, enforceability or infringement of any Patent covering the
manufacture, use or sale of Product or of any trademark rights relating to any Product shall be submitted to the Governmental Authority of competent jurisdiction in the country where such Patent or trademark exists. 

Section 12.6    Relationship of the Parties. The relationship of the Parties under this Agreement is that of
independent contractors. Nothing contained in this Agreement, nor the performance of any obligations under this Agreement, shall create an association, partnership, joint venture or relationship of principal and agent, master and servant, or
employer and employee between the Parties. No Party has any express or implied right or authority under this 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

52 

 
Agreement to assume or create any obligations or make any representations or warranties on behalf of or in the name of the other Party or such other Party’s Affiliates. 

Section 12.7    Assignment. Neither Party may assign, transfer or sublicense any of its rights or obligations
under this Agreement without the prior written consent of the other Party, except that any Party may assign this Agreement, without such consent, (a) in whole or in part to an Affiliate of such Party, upon written notice to the other Party of
such assignment, provided that such Party hereby guarantees the performance of any such Affiliate, or (b) in whole to any Third Party successor by merger, acquisition or sale of all or substantially all of such Party’s assets to which this
Agreement relates, upon written notice to the other Party of any such assignment, provided that such Third Party shall assume the obligations and covenants of the assigning Party under this Agreement. Except as expressly provided in this
Section 12.7, any attempted assignment or transfer of this Agreement shall be null and void. As a condition to the effectiveness of any permitted assignment of this Agreement, in whole or in part, the Assignee shall first agree in writing to
the provision contained in Section 8.5(c). The Parties intend that Alvogen will assign its distribution and payment obligations hereunder to Alvogen, Inc. or another Affiliate of Alvogen. 

Section 12.8    Binding Effect. This Agreement shall be binding upon and shall inure to the benefit of the
Parties and their respective permitted successors and assigns; and by their signatures hereto, each Party intends to, and does hereby, become bound. 

Section 12.9    Entire Agreement; Amendments. This Agreement, the Product Memo, the Common Interest Agreement,
and the schedules and exhibits hereto and thereto, contain the entire understanding of the Parties with respect to the subject matter herein, and cancel all previous agreements (oral and written including the Prior Agreements), negotiations and
discussions, dealing with the same subject matter. The Parties, from time to time during the Term, may modify any of the provisions hereof only by an instrument in writing duly executed by the Parties. 

Section 12.10    Severability. If any part or parts of this Agreement are held to be illegal, void or
ineffective, the remaining portions of this Agreement shall remain in full force and effect. If any of the terms or provisions of this Agreement are in conflict with any Applicable Law, then such term(s) or provision(s) shall be deemed inoperative
to the extent that they may conflict therewith, and shall be deemed to be modified so as to conform with such Applicable Law. In the event of any ambiguity respecting any term or terms hereof, the Parties agree to construe and interpret such
ambiguity in good faith in such a way as is appropriate to ensure its enforceability and viability. If any exclusive remedy provided hereunder is determined to be unenforceable, then the Party entitled to such remedy shall in lieu thereof be
entitled to such other remedies as are available to such Party under this Agreement or in law or equity under Applicable Law, subject in any case to the limitations imposed by, and other terms of, this Agreement. 

Section 12.11    Waiver. No failure or delay on the part of any Party in either exercising or enforcing any
right under this Agreement shall operate as a waiver of, or impair, any such right. No single or partial exercise or enforcement of any such right shall preclude any other or further 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

53 

 
exercise or enforcement thereof or the exercise or enforcement of any other right. No waiver of any such right shall have effect unless given in a signed writing. No waiver of any such right
shall be deemed a waiver of any other right. 
 Section 12.12    English Language. This Agreement shall be
written and executed in the English language. Any translation into any other language shall not be an official version hereof, and in the event of any conflict in interpretation between the English version and such translation, the English version
shall control. 
 Section 12.13    Counterparts. This Agreement may be executed in multiple counterparts,
and all such executed counterparts shall constitute the same agreement. 
 Section 12.14    Electronic Execution
and Delivery. A facsimile, PDF or other reproduction of this Agreement may be executed by one or more Parties, and an executed copy of this Agreement may be delivered by one or more Parties by facsimile,
e-mail or other electronic transmission device pursuant to which the signature of or on behalf of such Party can be seen, and such execution and delivery shall be considered valid, binding and effective for
all purposes. At the request of any Party, all Parties agree to execute an original of this Agreement as well as any facsimile or reproduction thereof. The Parties hereby agree that no Party shall raise the execution of a facsimile, PDF or other
reproduction of this Agreement, or the fact that any signature or document was transmitted or communicated by facsimile, e-mail or other electronic transmission device, as a defense to the formation of this
Agreement. 
 Section 12.15    Bankruptcy License Protection. Notwithstanding anything contained in
this Agreement to the contrary, all licenses and rights to licenses granted under or pursuant to this Agreement (including without limitation the Product License) are, and shall otherwise be deemed to be, for purposes of Section 365(n) of the
United States Bankruptcy Code (the “Bankruptcy Code”), licenses of rights to “intellectual property” as defined under Section 101(35A) of the Bankruptcy Code. The Parties agree that the “royalties” (as such
term is used in Section 365(n) of the Bankruptcy Code) to be paid under this Agreement are those payments described in Sections 4.4 and 4.5 of this Agreement. Alvogen, as the licensee of such rights under this Agreement, shall retain and may
fully exercise all of its rights and elections under the Bankruptcy Code, and upon commencement of a bankruptcy proceeding by or against Pfenex under the Bankruptcy Code, shall be entitled to a complete duplicate of, or complete access to (as
Alvogen deems appropriate), any such intellectual property and all embodiments of such intellectual property. Such intellectual property and all embodiments thereof shall be promptly delivered to Alvogen (i) upon any such commencement of a
bankruptcy proceeding upon written request therefor by Alvogen, unless Pfenex elects to continue to perform all of its obligations under this Agreement, or (ii) if not delivered under clause (i) above, upon the rejection of this Agreement
by or on behalf of Pfenex, upon written request therefor by Alvogen, and each Party hereby acknowledges and agrees that the foregoing shall serve as its consent to such transfer of the intellectual property and all embodiments thereof. The foregoing
provisions of this Section 12.15 are without prejudice to any rights Alvogen may have arising under the Bankruptcy Code or other Applicable Law. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

54 

 Section 12.16    Further Assurances. Each Party agrees to
execute, acknowledge and deliver such further instruments, and to do all such other acts, as may reasonably be necessary or appropriate in order to carry out the purposes and intent of this Agreement. 

Section 12.17    Compliance with Applicable Laws. Each Party shall comply with all Applicable Laws governing
its performance of the terms of this Agreement. 
 Section 12.18    Expenses. Except as otherwise expressly
set forth herein, each Party shall pay all costs and expenses incident to its negotiation and preparation of this Agreement and to its performance and compliance with all obligations contained herein on its part to be performed or complied with,
including the fees, expenses and disbursements of its counsel and other advisors. 

Section 12.19    Third Party Beneficiaries. Nothing herein expressed or implied is intended or shall be
construed to confer upon or give to any Person, other than the Parties and their respective permitted successors and assigns, any rights or remedies under or by reason of this Agreement, except as expressly contemplated by the terms of Article XI.

 Section 12.20    Equitable Remedies. Each Party acknowledges that a breach or threatened breach by such
Party of any of its obligations under this Agreement may give rise to irreparable harm to the other Party for which monetary damages may not be an adequate remedy and hereby agrees that, in the event of such breach or a threatened breach by any
Party of any such obligations, the other Party suffering such harm shall, in addition to any and all other rights and remedies that may be available to it in respect of such breach, be entitled to seek equitable relief, including a temporary
restraining order, an injunction or specific performance, subject in any case to Sections 12.4 and 12.5, without the obligation to post any bond. 

(The remainder of this page is intentionally left blank. The signature page follows.) 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

55 

 IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed as of the
Effective Date. 
  

			
	PFENEX INC.
		
	By:	 	 /s/ Eef Schimmelpennink

	Name:	 	Eef Schimmelpennink
	Title:	 	CEO
	
	ALVOGEN MALTA OPERATIONS LTD.
		
	By:	 	 /s/ Kirsten Burgess

	Name:	 	Kirsten Burgess
	Title:	 	VP, US Supply Chain

 [Signature Page to Development and License Agreement]

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 Exhibit 3.1(a) 

Development Plan 
 Summary 

[***] 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 Exhibit 5.2 

COGs Reduction Plan 
 [***] 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 Exhibit 8.7 

Press Release 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 

 
 DRAFT RELEASE 

Pfenex and Alvogen Enter into U.S. Agreement for Commercialization of PF708, a 

Therapeutic Equivalent Candidate to Forteo® 

- - - 
 SAN DIEGO, June XX, 2018
— Pfenex (NYSE American: PFNX) and Alvogen today announced entering into an agreement granting Alvogen exclusive rights to commercialize Pfenex’s lead drug candidate, PF708, a teriparatide therapeutic equivalent candidate to Eli
Lilly & Company’s Forteo®, in the United States. 
 This collaboration aligns the
interests and strengths of Pfenex and Alvogen in actions designed to secure regulatory approval and commercializing PF708 in the United States. Pfenex will continue to be responsible for development and registration of PF708, while Alvogen will
provide additional regulatory and development expertise. Alvogen will assume responsibility for costs related to litigation, commercial manufacturing and supply chain, and commercialization of PF708. In consideration for the licenses and other
rights granted in the development and license agreement, Pfenex received an upfront payment of $2.5 million and may be eligible to receive an additional $25M in support and regulatory milestone payments. Pfenex may also be eligible to receive a
50% gross profit split on sales if the product is rated as Therapeutic Equivalent (AP), and up to 40% if rated differently. 
 PF708 is being developed
through the 505(b)(2) regulatory pathway in the United States and references Forteo® which achieved $1.7 billion in global sales in 2017. Following the positive top-line PF708-301 study results as announced last month, Pfenex expects to submit a new drug application for PF708 to the U.S. Food and Drug Administration (FDA) in the third
quarter of 2018 leading to potential launch in the US, if approved by the FDA, as early as the third quarter of 2019. 
 “We are excited to partner
with Alvogen and believe that given their proven success in the US market it will maximize the value of PF708. Alvogen’s established commercial business with vast resources and experience will support us through the NDA submission process,
product launch and commercialization. When these operational benefits are combined with the favorable financial terms of the agreement, we see this collaboration as a significant step towards building long-term value for Pfenex stockholders,”
said Eef Schimmelpennink, Chief Executive Officer of Pfenex. “We have structured the agreement with Alvogen in a way that offers Pfenex experienced guidance and financial support as the PF708 commercialization program advances. By leading the
PF708 program up to potential approval, the Pfenex team will be building additional experience for the development of future programs, while also maintaining the potential for long term value capture through a significant share of gross
profits.” 
 “We are excited by the market opportunity that PF708 offers as a therapeutic equivalent candidate to Forteo® for the U.S. market. Forteo® achieved $1.7 billion in global sales in 2017,” stated Robert

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
Wessman, Chief Executive Officer of Alvogen. “The Alvogen team looks forward to working with the Pfenex team in preparing the PF708 program for the NDA submission to the FDA, and setting up
a robust commercial manufacturing and supply chain. Once PF708 receives market approval, we expect to quickly leverage our commercial operations in the U.S. in bringing the product to market. PF708 is highly complementary to our product portfolio in
the U.S., which is focused on complex high value generics and brands, including; niche generics, patches, semi-solids, controlled release oral drugs and injectables.”

About Pfenex Inc. 
 Pfenex Inc. is a clinical-stage
development and licensing biotechnology company focused on leveraging our Pfēnex Expression Technology® to improve protein therapies for unmet patient needs. Using the patented
Pfēnex Expression Technology platform, the company has created an advanced pipeline of therapeutic equivalents, vaccines, biologics and biosimilars. The company’s lead product candidates are PF708, a therapeutic equivalent candidate to
Forteo® (teriparatide) for the treatment of osteoporosis, and our novel anthrax vaccine candidates, Px563L and RPA563, funded through an advanced development contract with the U.S. government.
In addition, Pfenex is developing hematology/oncology products, including PF743, a recombinant crisantaspase, and PF745, a recombinant crisantaspase with half-life extension technology, in collaboration with Jazz Pharmaceuticals. Furthermore, the
company’s pipeline includes biosimilar candidates to Lucentis® and Neulasta®. 

About Alvogen 
 Alvogen is a global, privately owned
pharmaceutical company focused on developing, manufacturing and selling generic, brand, over-the-counter brands (OTC) and biosimilar products for patients around the
world. The company has commercial operations in 35 countries with 2,800 employees and operates four manufacturing and development hubs in the U.S., Romania, Korea and Taiwan. North America is Alvogen’s single largest market and other key
markets include: South Korea, Russia, Romania, Hungary, Ukraine, Taiwan, Japan and China. Learn more about Alvogen on www.alvogen.com. 
 Cautionary Note
Regarding Forward-Looking Statement – This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements because they
contain words such as “if,” “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,”
“contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these words or other similar terms or expressions that concern Pfenex’s expectations,
strategy, plans or intentions. Forward-looking statements in this press release include, but are not limited to, statements regarding the future potential of PF708, including development and commercialization of PF708; the potential to receive
future milestone and royalty payments under Pfenex’s agreement with Alvogen; the expected timing of Pfenex’s submission of the NDA for PF708; the expectation for PF708 to obtain marketing approval in the United States; Pfenex’s
expectation to develop the product under the 505(b)(2) regulatory pathway in the United States; the belief that this agreement will help advance development and commercialization of PF708; potential market opportunities for PF708; the potential for
the collaboration to support the PF708 program for the NDA submission to the FDA; and the belief that Alvogen will be able to quickly leverage its commercial operations in the U.S. in bringing PF708 to market. Actual results may differ materially
from those indicated by these forward-looking statements as a result of the uncertainties inherent in the clinical drug development process, including, without limitation, challenges in successfully demonstrating the efficacy and safety of product
candidates; the pre-clinical and clinical results for product candidates, which may not support further development of product candidates or may require additional clinical trials or modifications of ongoing
clinical trials or regulatory pathways; challenges related to commencement, 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
patient enrollment, completion, and analysis of clinical trials; Pfenex’s ability to obtain additional funding to support its business activities and establish and maintain strategic
business alliances and new business initiatives; Pfenex’s dependence on third parties for development, manufacture, marketing, sales and distribution of products; unexpected expenditures; and difficulties in obtaining and maintaining
intellectual property protection for product candidates. Information on these and additional risks, uncertainties, and other information affecting Pfenex’s business and operating results is contained in Pfenex’s Quarterly Report on
Form 10-Q for the quarter ended March 31, 2018 and in Pfenex’s subsequent reports filed with the Securities and Exchange Commission. The forward-looking statements in this press release are
based on information available to Pfenex as of the date hereof, and Pfenex disclaims any obligation to update any forward-looking statements, except as required by law. 

Pfenex investors and others should note that we announce material information to the public about the Company through a variety of means, including our
website (http://www.pfenex.com/), our investor relations website (http://pfenex.investorroom.com/), press releases, SEC filings, public conference calls, corporate Twitter account (https://twitter.com/pfenex), Facebook page (https://www.facebook.com/Pfenex-Inc-105908276167776/timeline/), and LinkedIn page (https://www.linkedin.com/company/pfenex-inc) in
order to achieve broad, non-exclusionary distribution of information to the public and to comply with our disclosure obligations under Regulation FD. We encourage our investors and others to monitor and review
the information we make public in these locations as such information could be deemed to be material information. Please note that this list may be updated from time to time. 

For further information: 
 Susan A. Knudson 

Chief Financial Officer 
 Pfenex Inc. 

(858) 352-4324 

sknudson@pfenex.com 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 Exhibit 12.5 

Alternative Dispute Resolution 

The Parties recognize that bona fide disputes as to certain matters may arise from time to time during the Term of this Agreement which relate
to any Party’s rights or obligations. To have such a dispute resolved by this Alternative Dispute Resolution (“ADR”) provision, a Party first must comply with Section 12.4 of the Agreement to which this is an exhibit. If
the matter has not been resolved in accordance with such Section 12.4, a Party may initiate an ADR proceeding as provided herein. The Parties shall have the right to be represented by counsel in such a proceeding. 

1.    To begin an ADR proceeding, a Party shall provide written notice to the other Party of the issues to be resolved by
ADR in accordance with this Exhibit 12.5. Within fourteen (14) days after its receipt of such notice, the other Party may, by written notice to the Party initiating the ADR, add additional issues to be resolved within
the same ADR. 
 2.    Unless either Party requests otherwise in writing within the fourteen (14) day period
described in Paragraph 1 above, the issue shall be resolved in accordance with the Fast Track Mediation and Arbitration Rules of Procedure as administered by JAMS (formerly known as Judicial Arbitration and Mediation Services)
(“JAMS”) by a single arbitrator appointed in accordance with such rules and subject to the provisions of Paragraphs 3 - 13 below. 

3.    Within twenty-one (21) days following receipt of the original ADR
notice, the Parties shall select a mutually acceptable neutral to preside in the resolution of any disputes in this ADR proceeding (each, a “Neutral”). If the Parties are unable to agree on a mutually acceptable Neutral within such
period, a Party may request the President of JAMS, 18881 Von Karman Ave., Suite 350, Irvine, CA 92612, to select a Neutral pursuant to the following procedures: 

(a)    JAMS shall submit to the Parties a list of not less than five (5) candidates within fourteen
(14) days after receipt of the request, along with Curriculum Vitae for each candidate. No candidate shall be an employee, director, or shareholder of any Party or any of their Affiliates. Each candidate submitted by JAMS shall (i) be an
attorney licensed to practice law for at least twenty (20) years in the United States; and (ii) have material legal or business experience in the pharmaceutical industry. 

(b)    Such list shall include a statement of disclosure by each candidate of any circumstances likely to
affect his or her impartiality. 
 (c)    Each Party shall number the candidates in order of preference
(with the number one (1) signifying the greatest preference) and shall deliver the list to JAMS within seven (7) days following receipt of the list of candidates. If a Party believes a conflict of interest exists regarding any of the
candidates, that Party shall provide a 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
written explanation of the conflict to JAMS along with its list showing its order of preference for the candidates. Any Party failing to return a list of preferences on time shall be deemed to
have no order of preference. 
 (d)    If the Parties collectively have identified fewer than three
(3) candidates deemed to have conflicts, JAMS immediately shall designate as the Neutral the candidate for whom the Parties collectively have indicated the greatest preference. If a tie should result between two candidates, JAMS may designate
either candidate. If the Parties collectively have identified three (3) or more candidates deemed to have conflicts, JAMS shall review the explanations regarding conflicts and, in its sole discretion, may either (i) immediately designate
as the Neutral the candidate for whom the Parties collectively have indicated the greatest preference, or (ii) issue a new list of not less than five (5) candidates, in which case the procedures set forth in subparagraphs 2(a)–2(d)
shall be repeated. 
 4.    No earlier than forty-five (45) days or later than ninety (90) days after
selection, the Neutral shall hold a hearing to resolve each of the issues identified by the Parties. The ADR proceeding shall take place in San Diego, California. 

5.    At least fourteen (14) days prior to the hearing, each Party shall submit the following to the other Party and
the Neutral: 
 (a)    a copy of all exhibits on which such Party intends to rely in any oral or written
presentation to the Neutral; 
 (b)    a list of any witnesses such Party intends to call at the hearing,
and a short summary of the anticipated testimony of each witness; 
 (c)    a proposed ruling on each
issue to be resolved, together with a request for a specific damage award or other remedy for each issue. The proposed rulings and remedies shall not contain any recitation of the facts or any legal arguments and shall not exceed one (1) page
per issue. 
 (d)    a brief in support of such Party’s proposed rulings and remedies, provided that
the brief shall not exceed thirty (30) double-spaced pages. This page limitation shall apply regardless of the number of issues raised in the ADR proceeding. 

Except as expressly set forth in subparagraphs 5(a)–5(d), no discovery shall be required or permitted by any means, including depositions,
interrogatories, requests for admissions, or production of documents. 
 6.    The hearing shall be conducted on
consecutive days and shall be governed by the following rules: 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 (a)    Each Party shall be entitled to ten
(10) hours of hearing time to present its case. The Neutral shall determine whether each Party has had the ten (10) hours to which it is entitled. 

(b)    Each Party shall be entitled, but not required, to make an opening statement, to present regular and
rebuttal testimony, documents or other evidence, to cross-examine witnesses, and to make a closing argument. Cross-examination of witnesses shall occur immediately after their direct testimony. Opening statements, closing statements, rebuttal
testimony and cross-examination time shall be charged against the Party conducting same. 
 (c)    The
Party initiating the ADR shall begin the hearing and, if it chooses to make an opening statement, shall address not only issues it raised but also any issues raised by the responding Party. The responding Party, if it chooses to make an opening
statement, also shall address all issues raised in the ADR. Thereafter, the presentation of regular and rebuttal testimony and documents, other evidence, and closing arguments shall proceed in the same sequence. 

(d)    Except when testifying, witnesses shall be excluded from the hearing until closing arguments. 

(e)    Settlement negotiations, including any statements made therein, shall not be admissible under any
circumstances. Affidavits prepared for purposes of the ADR hearing also shall not be admissible. Live videoconference or telephonic testimony will be permitted at the discretion of the Neutral. The Neutral shall have sole discretion with regards to
the exercise of its subpoena powers to compel the attendance of witnesses and the production of documents from Third Parties. As to all other matters, the Neutral shall have sole discretion regarding the admissibility of any evidence. 

7.    Within ten (10) days following completion of the hearing, each Party may submit to the other Party and the
Neutral a post-hearing brief in support of its proposed rulings and remedies, provided that such brief shall not contain or discuss any new evidence and shall not exceed thirty (30) pages. This page limitation shall apply regardless of the
number of issues raised in the ADR proceeding. 
 8.    The Neutral shall rule on each disputed issue within twenty-one (21) days following completion of the hearing. Such ruling shall adopt in its entirety the proposed ruling and remedy of one of the Parties on each disputed issue but may adopt one Party’s
proposed rulings and remedies on some issues and the other Party’s proposed rulings and remedies on other issues. The Neutral shall not issue any written opinion or otherwise explain the basis of the ruling. 

9.    The Neutral shall be paid a reasonable fee plus expenses. These fees and expenses, along with the reasonable legal
fees and expenses of the prevailing Party (including all 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
expert witness fees and expenses), the fees and expenses of a court reporter, and any expenses for a hearing room, shall be paid as follows: 

(a)    If the Neutral rules in favor of one Party on all disputed issues in the ADR, the losing Party shall
pay one hundred percent (100%) of such fees and expenses. 
 (b)    If the Neutral rules in favor of one
Party on some issues and the other Party on other issues, the Neutral shall issue with the rulings a written determination as to how such fees and expenses shall be allocated between the Parties. The Neutral shall allocate fees and expenses in a way
that bears a reasonable relationship to the outcome of the ADR, with the Party prevailing on more issues, or on issues of greater value or gravity, recovering a relatively larger share of its legal fees and expenses. 

10.    The rulings of the Neutral and the allocation of fees and expenses shall be binding,
non-reviewable, and non-appealable to the extent allowed by Applicable Law, and may be entered as a final judgment in any court having jurisdiction. 

11.    Except as provided in paragraph 10 or as required by Applicable Law, the existence of the dispute, any settlement
negotiations, the ADR hearing, any submissions (including exhibits, testimony, proposed rulings, and briefs), and the rulings shall be deemed Confidential Information of both Parties. The Neutral shall have the authority to impose sanctions for
unauthorized disclosure of Confidential Information. 
 12.    The Neutral may not award punitive damages. The Parties
hereby waive the right to the award of punitive damages. 
 13.    The hearings shall be conducted in the English
language. 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00286-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00286-of-00352.parquet"}]]